Satixfy Communications (SATX) 20-F 29 Mar 24 2023 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information shares in Thousands	12 Months Ended
	Dec. 31, 2023 shares
Entity Addresses [Line Items]
Entity Registrant Name	SatixFy Communications Ltd.
Entity Central Index Key	0001915403
Document Type	20-F
Document Period End Date	Dec. 31, 2023
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Common Stock, Shares Outstanding	83,114,193
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	L3
Entity File Number	001-41544
Entity Address, Address Line One	12 Hamada St
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	670315
Entity Address, Country	IL
Title of 12(b) Security	Ordinary Shares, no par value
Trading Symbol	SATX
Security Exchange Name	NYSE
Document Accounting Standard	International Financial Reporting Standards
Document Registration Statement	false
Auditor Firm ID	1185
Auditor Location	Tel-Aviv, Israel
Auditor Name	Ziv Haft
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	1633 Broadway
Entity Address, City or Town	New York
Entity Address, Postal Zip Code	10019
Contact Personnel Name	Oded Har-Even, Esq.
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	660.3000
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	28 HaArba’a St. HaArba’a Towers,
Entity Address, Postal Zip Code	6473925
Contact Personnel Name	Reut Alfiah, Adv.
Entity Address, State or Province	NY
City Area Code	972
Local Phone Number	74.758.0480

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 13,979	$ 11,934
Trade accounts receivable	2,260	1,295
Contract Assets	4,091	5,035
Prepaid expenses and other	2,332	3,648
Government departments and agencies receivables	3,076	6,156
Related parties	75	157
Derivatives FPA	0	12,775
Promissory Notes	20,000	0
Inventory	1,475	831
Total current assets	47,288	41,831
NON-CURRENT ASSETS:
Other long-term receivables	2,000	0
Right-of-use assets, net	2,235	2,794
Property, plant and equipment, net	1,420	1,643
Investment in Jet Talk	1,551	1,777
Long term Deposits	208	203
Derivatives FPA	0	28,077
Total non-current assets	7,414	34,494
TOTAL ASSETS	54,702	76,325
CURRENT LIABILITIES:
Trade payables	1,378	1,459
Contract Liabilities	1,720	622
ESA advance payments	3,842	5,800
Prepayment from Customer	3,858	3,301	[1]
Advanced payments from MDA against future orders	28,138	8,875	[1]
Lease liabilities	639	1,021
Other accounts payable and accrued expenses	9,704	7,843
Related Parties	740	408
Total current liabilities	50,019	29,329
NON-CURRENT LIABILITIES:
Long term loans from financial institutions, net	59,792	54,926
Lease liabilities	2,067	2,280
Derivatives Instruments Liabilities	114	20,305
Other long-term liabilities	1,496	1,107
Total non-current liabilities	63,469	78,618
SHAREHOLDERS' DEFICIT:
Share Capital	0	0
Share Premium	451,093	446,488
Capital reserves	1,444	3,498
Accumulated deficit	(511,323)	(481,608)
Total shareholders' deficit	(58,786)	(31,622)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 54,702	$ 76,325
[1]Reclassified

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Development services and preproduction	$ 8,249	$ 10,081	$ 19,237
Sale of products	2,481	545	2,483
Total revenues	10,730	10,626	21,720
Cost of sales and services:
Development services and preproduction	4,930	4,166	7,326
Sale of products	1,008	332	1,517
Total cost of sales and services	5,938	4,498	8,843
Gross profit	4,792	6,128	12,877
Research and development expenses, Net	29,126	16,842	17,944
Selling and marketing expenses	2,866	2,335	1,752
General and administrative expenses	14,561	9,249	3,735
Loss from operations	(41,761)	(22,298)	(10,554)
Finance Income	83	17	0
Finance Expenses	(12,129)	(9,919)	(4,399)
Derivatives revaluation	(17,217)	(37,377)	(199)
Other income	41,657	5,474	0
Listing Expenses	0	(333,326)	0
Company's share in the loss of a company accounted by equity method, net	(226)	(360)	(1,898)
Loss before income taxes	(29,593)	(397,789)	(17,050)
Tax expenses	(122)	0	0
Loss for the period	(29,715)	(397,789)	(17,050)
Other comprehensive income (loss) net of tax:
Exchange gain (loss) arising on translation of foreign operations	(609)	3,272	1,131
Total comprehensive loss for the period	$ (30,324)	$ (394,517)	$ (15,919)
Basic loss per share (in dollars)	$ (0.37)	$ (13.25)	$ (0.91)
Diluted loss per share (in dollars)	$ (0.37)	$ (13.25)	$ (0.91)
Basic weighted average common shares outstanding	80,974,653	30,030,805	18,732,473
Diluted weighted average common shares outstanding	80,974,653	30,030,805	18,732,473

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($) $ in Thousands	Ordinary shares	Preferred Shares A	Preferred Shares B	Preferred Shares C	Share capital		Share premium	Accumulated deficit	Capital reserves	Total
Balance at the beginning at Dec. 31, 2020					$ 4		$ 45,990	$ (66,769)	$ (905)	$ (21,680)
Balance at the beginning (in shares) at Dec. 31, 2020	18,722,010	7,638,647	4,999,651	895,710
Exercise of employee's options					0	[1]	64	0	0	64
Exercise of employee's options (in shares)	61,158
Share based payments					0	[1]	149	0	0	149
Comprehensive loss for the year					0		0	(17,050)	1,131	(15,919)
Balance at the end at Dec. 31, 2021					4		46,203	(83,819)	226	(37,386)
Balance at the end (in shares) at Dec. 31, 2021	18,783,168	7,638,647	4,999,651	895,710
Shares issued to Financial Institutions					0		1,978	0	0	1,978
Shares issued to Financial Institutions (in shares)	846,432
Exercise of employee's options							101	0	0	101
Exercise of employee's options (in shares)	236,446
Warrant exercised					0		5,399	0	0	5,399
Warrant exercised (in shares)			57,660	860,802
Share based payments						[2]	570	0	0	570
Issuance of shares following SPAC transaction					(4)		339,858	0	0	339,854
Issuance of shares following SPAC transaction (in shares)	56,647,836	(7,638,647)	(5,057,311)	(1,756,512)
SPAC Exercise of warrants (in shares)	2,553,692
SPAC Exercise of warrants					0		2,381	0	0	2,381
Issuing shares as part of FPA					0		49,998	0	0	49,998
Issuing shares as part of FPA (in shares)	1,605,100
Comprehensive loss for the year					0		0	(397,789)	3,272	(394,517)
Balance at the end at Dec. 31, 2022					0		446,488	(481,608)	3,498	(31,622)
Balance at the end (in shares) at Dec. 31, 2022	80,672,674	0	0	0
Shares issued to employees					0		27	0	0	27
Shares issued to employees (in shares)	940,953
Shares issued to Financial Institutions					0		1,628	0	0	1,628
Shares issued to Financial Institutions (in shares)	1,500,566
Share based payments					0		2,950	0		2,950
Comprehensive loss for the year					0			(29,715)	(609)	(30,324)
Currency translation reserve realization due the sell of SSS					0		0	0	(1,445)	(1,445)
Balance at the end at Dec. 31, 2023					$ 0		$ 451,093	$ (511,323)	$ 1,444	$ (58,786)
Balance at the end (in shares) at Dec. 31, 2023	83,114,193	0	0	0
[1]Represents an amount less than one thousand.[2]Represents an amount less than one thousand.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Loss for the year	$ (29,715)	$ (397,789)	$ (17,050)
Adjustments to reconcile net profit to net cash provided by operating activities:
Depreciation and amortization	1,245	1,162	1,421
Company's share in the loss of a company accounted by equity method, net	226	360	1,898
Finance expenses on loans	6,613	5,211	917
Change in the fair value of derivatives	17,227	37,374	200
Share based payments	2,950	570	149
Adjustment to Loss due to SPAC transaction	0	332,272	0
Decrease (Increase) in trade accounts receivable	(885)	(587)	(305)
Decrease (Increase) in contract assets	1,220	537	(4,119)
Increase in inventory	(644)	(146)	(10)
Decrease (Increase) in other current assets	3,508	(7,007)	3,256
Increase (Decrease) in trade payables	(75)	(6,236)	1,461
Increase (Decrease) in ESA prepayments	(1,268)	(7,609)	1,882
Decrease in deferred revenues	0	0	(612)
Increase (Decrease) in other accounts payable and accrued expenses	(2,601)	(1,571)	3,282
Increase in prepayments from customers	682	2,936	1,504
Increase Prepayments from MDA	18,139	8,875	0
MDA Agreement	(41,657)	0	0
Increase in other long-term liabilities	300	0	0
Increase in liability for royalties payable	100	168	260
Net cash used in operating activities	(24,635)	(31,480)	(5,866)
Cash flows from investing activities
Decrease (Increase) in long-term bank deposit	(7)	(11)	201
Proceeds from selling a subsidiary	17,583	0	0
Purchase of property, plant and equipment	(235)	(571)	(211)
Net cash provided (used in) investing activities	17,341	(582)	(10)
Cash flows from financing activities
Receipt of long-term loans from a financial institution	0	52,837	7,300
Repayment of loan to shareholder	0	(5,000)	0
Repayment of loans from banks	0	(13,818)	(2,930)
Repayment of royalty liability	(11)	(429)	(488)
Payments of lease liabilities	(927)	(1,029)	(1,191)
Issuance of shares- SPAC transactions	0	1,362	0
Option exercises to shares by employees	26	100	64
Exercise of Warrants, net	0	6,500	0
Issuance of shares to FPA	10,026	0	0
Net cash provided by financing activities	9,114	40,523	2,755
Increase (decrease) in cash and cash equivalents	1,820	8,461	(3,121)
Cash and cash equivalents balance at the beginning of the year	11,934	3,854	6,983
Effect of changes in foreign exchange rates on cash and cash equivalents	225	(381)	(8)
Cash and cash equivalents balance at the end of the year	13,979	11,934	3,854
Appendix A – Cash paid and received during the year for:
Interest paid	1,241	921	1,625
Appendix B – Non Cash transactions during the year for:
Purchase of Fixed Assets in Credit	0	319	0
Issuance of shares against liability	0	49,998	0
Issuance of shares against loan	1,628	1,978	0
Issuance of shares against warrants	0	$ 1,280	$ 0
Appendix C – Proceeds from selling a subsidiary
Cash that was sold	417
Prepaid expenses and other	218
Short term Deposits	85
Other accounts receivables	932
Property, plant and equipment, net	150
Trade accounts payable	(175)
Contract liabilities	(96)
Other accounts payable	(585)
ESA Prepayments	(994)
Related party	(164)
Capital Gain	41,657
Capital reserve	(1,445)
Net assets and liabilities	40,000
Less assets received
Promissory Notes	20,000
Other long-term receivables	2,000
Cash received	18,000
Cash sold	(417)
Net Cash inflows	$ 17,583

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2023
Disclosure Of General Information About Financial Statements Abstract
GENERAL	NOTE 1 - GENERAL: a. Satixfy Communications LTD (hereinafter: the "Company") was originally incorporated in Hong Kong as Satixfy Limited in 2012 and in 2020 was reorganized and re-incorporated in Israel as a private limited company, in accordance with the provisions of the Israeli Companies Law with the approval from the Israeli Tax Authorities for tax exemption in accordance with the provisions of section 104B (f) of the Income Tax Ordinance. b. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of December 31, 2023, we had incurred accumulated losses of $511 million. In October 2023, The Company announced the completion of the sale of one of its UK subsidiaries (Satixfy Space Systems UK Ltd) to MDA Ltd (See Note 3) for a total consideration of $40 million combined with additional $20 million in advanced payments against delivery of future products. The Company believes that the funds received and yet to be received as part of the MDA agreement including our mature pipeline from existing and new customers combined with the cost reduction associated with the MDA agreement and a further cost reduction plan and the Equity line of credit with Cantor Fitzgerald & Co (See Note 3), will generate sufficient cash for the foreseeable future. c. Business Combination Agreement SPAC Transaction ("Business Combination Agreement" OR "Transactions"): On March 8, 2022, the Company and one of its subsidiaries, SatixFy MS, which was incorporated in 2022 for that purpose, entered into the Business combination agreement with Endurance Acquisition Corp. (“Endurance”). Under that agreement, SatixFy MS merged into Endurance, with Endurance continuing as the surviving company and becoming the Company’s direct, subsidiary. The Business Combination Agreement, as amended, and the related transactions (the "SPAC merger") were completed on October 27, 2022 (the “Closing”). As a result of the Business Combination, the Company recorded a gross increase in cash of $20 million and had $18.7 million expenses in cash related to the Transactions. The Business Combination was accounted for as a capital reorganization, with no goodwill or other intangible assets recorded, in accordance with IFRS 3, Business Combination. The Company is the accounting acquirer and SatixFy Ordinary Shares were registered under the U.S. Securities Exchange Act of 1934, as amended, and listed on the NYSE American, LLC (“NYSE”). Concurrently with the execution of the Business Combination Agreement, the Company entered into the Equity Line of Credit with CF Principal Investments LLC, an affiliate of Cantor Fitzgerald & Co. (“CF”), pursuant to which the Company may issue and sell to CF, from time to time and subject to the conditions in the related purchase agreement, up to an aggregate amount of $77.25 million in the Company’s Ordinary Shares for aggregate gross proceeds to the Company of up to $75 million after deducting the applicable purchase price discount on sales to CF thereunder. In addition, the company entered into an OTC Equity Prepaid Forward Transaction (the “Forward Purchase Transaction” or "FPA") with Vellar Opportunity Fund SPV LLC – Series 7 (“Vellar”) and ACM ARRT G LLC (“ACM”), which was terminated on October 31, 2023 (“Vellar”, together with ACM, the “Seller”) (see note 17). As part of the Business Combination Agreement, the Company has also issued different derivatives (see note 15). d. The Company and its subsidiaries are engaged in the development and marketing of integrated circuit products for specific applications, antennas and terminals used for satellite communications. The Company has developed a new generation of integrated silicon chips for modems and antennas based on its own proprietary technology and provides end-to-end solutions for the satellite communications industry, including terminals, payload subsystems and hubs. The Company develops its advanced chips (Application Specific Integrated Circuit chips (ASICs) and Radio Frequency Integrated Circuit chips (RFICs)) based on technology designed to meet a variety of applications and services, such as broadband aviation, IOT, mobility and maritime, and operating on GEO, LEO and MEO satellites. The Company’s technology includes electronically steered antenna arrays, forming and design of digital beams, beam hopping, on-board processing payload chips and software-defined radio (SDR) modem chips. The affiliated company "Jet Talk" is engaged in the development and marketing of a unique antenna for IFC passenger aircraft and computers that receive broadband video transmissions from satellites. e. The Company operates primarily through five wholly owned subsidiaries: Satixfy Israel LTD, Satixfy UK Limited, Satixfy Space Systems UK (hereinafter: “SSS) (which was sold in October 2023 to MDA- See note 3), Satixfy Bulgaria Eood and SatixFy US LLC (collectively together with Company, the "Group"), all of which have been consolidated in these consolidated financial statements. Name Holding percentage Held By Country of incorporation 2023 2022 Satixfy Israel LTD. 100 % 100 % Satixfy Communications LTD. Israel Satixfy UK 100 % 100 % Satixfy Communications LTD. England and Wales Satixfy Space Systems UK (See Note 3) 0 % 100 % Satixfy Communications LTD. England and Wales Satixfy Bulgaria 100 % 100 % Satixfy UK Bulgaria Satixfy US LLC 100 % 100 % Satixfy Communications LTD. USA Endurance Acquisition Corporation 100 % 100 % Satixfy Communications LTD. Cayman Islands In addition, the Company's holds 51% of the shares of the following entity (see also Note 7): Name Holding percentage as of December 31, Held By Country of incorporation 2023 2022 Jet talk Limited (“Jet-Talk”) 51 % 51 % Satixfy UK UK f. Russia- Ukraine war: The Russia-Ukraine war poses indirect but unpredictable risks of disruption to the Company’s business mostly associated with its current and prospective customers which have experienced delays in deploying their satellites. Additionally, the Russia-Ukraine conflict has an adverse impact on the supply of certain commodities used in the fabrication of silicon chips (such as neon gas), of which Ukraine and Russia were significant producers. The Company's ability to mitigate the potential adverse impacts is limited, as the impacts on it are largely indirect. The effects of sanctions implemented by certain governments in response to the conflict may also adversely affect the Company’s industry, including chip supply chains, to the extent that they lead to higher energy and manufacturing costs, lower economic growth, or deferrals of investment in satellite communications technology. As of the date of approval of this report, the Company's management has not identified any difficulties in the Company's liquidity due to the Russia-Ukraine war or a material impact on the availability of financing sources. g. Israel - Hamas War: We are incorporated under the laws of the State of Israel, and our principal offices are located in Israel. Accordingly, political, economic, and geo-political instability in Israel may affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations and solution development and cause any future sales to decrease. On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. The intensity and duration of Israel’s current war is difficult to predict, as are such war’s implications on our business and operations. While none/some of our supply chains have been impacted since the war broke out on October 7, 2023, the ongoing war may create supply and demand irregularities in Israel’s economy in general or lead to macroeconomic indications of a deterioration of Israel’s economic standing, which may have a material adverse effect on us and our ability to effectively conduct our operations. Moreover, we cannot predict how this war will ultimately affect Israel’s economy in general, which may involve a downgrade in Israel’s credit rating by rating agencies (such as the recent downgrade by Moody’s of its credit rating of Israel from A1 to A2, as well as the downgrade of its outlook rating from “stable” to “negative”). In connection with the Israeli security cabinet’s declaration of war against Hamas and possible or currently occurring hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service. Five of our employees, none of whom are members of management, have been called to active military duty since October 7, 2023. Some of these employees have since returned, but there can be no assurance that they will not be called to military service again. In addition, we rely on service providers located in Israel and our employees or employees of such service providers may be called for service in the current or future wars or other armed conflicts with Hamas and such persons may be absent from their positions for a period of time. As of March 28, 2024, any impact as a result of the number of absences of our personnel and personnel at our service providers or counterparties located in Israel has been manageable. However, military service call ups that result in absences of personnel from our service providers or contractual counterparties in Israel may disrupt our operations and absences for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations. Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon has also launched missile, rocket, and shooting attacks against Israeli military sites, troops, and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on sites belonging to Hezbollah in southern Lebanon. It is possible that other terrorist organizations, including Palestinian military organizations in the West Bank or the Houthis in Yemen, as well as other hostile countries, such as Iran, will join the hostilities. Such hostilities may include terror and missile attacks. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: The significant accounting policies used in the preparation of the financial statements, on a consistent basis, are: A. Basis of preparation: These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and Interpretations (collectively “IFRS”) . The financial statements have been prepared under the historical cost convention except for certain financial liabilities which are measured at fair value untit conversion. The Company has elected to present the consolidated statements of comprehensive loss using the function of expense method. B. Basis of consolidation: Subsidiaries: Where the Company has control over an investee, it is classified as a subsidiary. The Company controls an investee if all three of the following elements are present: power over the investee, exposure to variable returns from the investee, and the ability of the investor to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. The consolidated financial statements present the results of the Company and its subsidiaries as if they formed a single entity. Intercompany transactions and balances between Group companies are therefore eliminated in full. In addition, the financial statements of the subsidiaries were prepared using a consistent accounting policy with the Company regarding similar transactions and events in similar circumstances. Investments in affiliated companies and joint ventures: When the Company has the ability to influence the business operation of another entity, but the influence does not constitute control, then the Company has a significant influence which will be presented as an affiliate company and accounted for based on the equity method. Potential voting rights which can be exercised on an immediate basis also taking into account as part of the above influence. The holding in an affiliate company is presented based on the equity method unless the investment is held for sale. The financial statements of the affiliated company have been prepared using the same accounting policy of the Company. Any goodwill arising from the affiliated company purchase is part of the investment and is not amortized unless there is objective evidence for impairment. If the Company's share in the losses of an affiliated company or joint venture is equal to or exceeds its rights in the affiliated company or in the joint venture, the Company ceases to recognize its share in additional losses. Once the Company's rights have been reduced to zero, the Company recognizes additional losses only to the extent that it has incurred legal or implied liabilities or to the extent that payments have been made for the affiliated company or for the joint venture. The Company recognizes the gains that arise thereafter only when the Company's share in the profits equals the share in unrecognized losses. The Company performs an impairment test (see Note 2.T below) for a net investment in an affiliated company or in a joint venture as a whole when there is objective evidence of impairment of the investment. An impairment loss is allocated to an investment as a whole. The Company ceases to use the equity method as of the date on which an investment ceases to be an affiliated company or joint venture. Any investment remaining in the former affiliate or former joint venture is measured at fair value. The difference between the fair value of the remaining investment and any consideration from the realization of part of the investment and the book value of the investment at the time the use of the equity method is discontinued is recognized in profit or loss. Amounts previously recognized in other comprehensive income with respect to the same investment are treated in the same manner that would have been required if the invested entity had itself realized the related assets or related liabilities. Transactions eliminated on consolidation: Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. Unrealized gains arising from transactions with associates and joint ventures are eliminated to the extent of the Group’s interest in these investments. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment. C. Use of critical estimates and assumptions in the preparation of the financial statements: The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. By their nature, these estimates are subject to measurement uncertainty and are reviewed periodically and adjustments, if necessary, are made in the year which they are identified. Actual results could differ from those estimates. The following is a description of assumptions about the future and other factors for uncertainty in estimates at the end of the reporting period, which results in a significant risk that will result in material correlation to book values ​​of assets and liabilities during the next reporting period: Useful life of fixed assets and intangible assets – Useful life is based on management’s estimates of the period in which the assets will generate income, which are reviewed periodically for the purpose of examining the adequacy of these estimates. Changes in management’s estimates may lead to material changes in depreciation expense recognized in profit or loss. Fair value of financial instruments – The fair value of financial instruments that are not quoted in an active market is measured in accordance with model-based valuation techniques. These techniques are significantly influenced by assumptions that serve as a basis for calculation, such as capitalization rates and estimates of future cash flows. Inventory - The net realizable value of the inventory is reviewed at the end of each reporting period. Factors that may affect selling prices include the existing market demand for the company's inventory, the activity of competitors in the market, superior technology in the market, the prices of raw materials and the bankruptcy of customers and suppliers. Estimates of Receipts or Payments of Financial Instruments - If the Company updates the estimates of receipts or payments of financial instruments, it adjusts the value in the books of the financial instrument to reflect the actual cash flows and the updated estimate of the cash flows. Contracts with customers - Measuring the progress of performance commitments that exist over time the company estimates the total cost of completing each project based on estimates of material costs, labor costs, subcontractor performance and more. D. Foreign currency: The consolidated financial statements are prepared in U.S. Dollars (which is the functional and reporting currency of the Company). Transactions and balances in foreign currencies are converted into US Dollars in accordance with the principles set forth by International Accounting Standard (IAS) 21 "The Effects of Changes in Foreign Exchange Rates". Accordingly, transactions and balances have been converted as follows: • Monetary assets and liabilities – at the rate of exchange applicable at the consolidated statements of financial position date. • Exchange gains and losses from the aforementioned conversion are recognized in the statement of comprehensive loss. • Expense items – at exchange rates applicable as of the date of recognition of those items. • Non-monetary items are converted at the rate of exchange used to convert the related consolidated statements of financial position items (i.e., at the time of the transaction). Foreign operations: On consolidation, the results of foreign operations are translated into US Dollars at exchange rates ruling when the transactions took place. All assets and liabilities of foreign operations, including goodwill arising on the acquisition of those operations, are translated at the rate ruling at the reporting date. Exchange rate differences arising on translating the opening net assets at opening rate and the results of foreign operations at actual rate of exchange are recognized in other comprehensive income and accumulated in the foreign exchange reserve. Exchange differences recognized in profit or loss in the Group entities' separate financial statements on the translation of long-term monetary items forming part of the Group's net investment in the foreign operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange reserve on consolidation. On disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to that operation up to the date of disposal are classified to profit or loss as part of the profit or loss on disposal. E. Cash and cash equivalents: Cash equivalents are considered by the Company to be highly liquid investments, including, inter alia, short-term deposits with banks where the maturity of which does not exceed three months at the time of deposit and which are not restricted. Overdrafts, which are due on demand and form an integral part of the Company's cash management, were included as a component of cash and cash equivalents for the purposes of presenting the statement of cash flows. F. Linkage: Assets and liabilities linked to the consumer price index were included according to the appropriate index for each asset or liability. CPI-linked loans are measured at reduced cost when the balance at the end of the reporting period is CPI-linked. G. Provisions: Provisions are recognized when the Company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result, and that outflow can be reliably measured. Provisions are measured using the best estimate of the amounts required to settle the obligation at the end of the reporting period. The effect of the time value is material, the amount of the provision is measured according to the present value of the projected expenses that will be required to settle the obligation. The reduction of a provision is recognized in profit or loss as the reduction of the appropriate consequential item when the Company actually bears it or at the date of its termination, whichever is later. H. Research and development costs: Expenditure on research activities is recognized in profit or loss as incurred. Expenditure incurred on development activities including the Company’s development is capitalized where the expenditure will lead to new or substantially improved products and only if all the following can be demonstrated: • the product is technically and commercially feasible; • the Company intends to complete the product so that it will be available for use or sale; • the Company has the ability to use the product or sell it; • the Company has the technical, financial and other resources to complete the development and to use or sell the product; • the Company can demonstrate the probability that the product will generate future economic benefits; and. • the Company is able to measure the expenditure attributable to the product during the development. Recognition of costs in the carrying amount of an intangible asset, ceases, when the asset is in the condition necessary for it to be capable of operating in the manner intended by management. Capitalized development costs are amortized on a straight-line basis over their estimated useful lives once the development is completed and the assets are in use. Subsequent expenditure on capitalized intangible assets is capitalized only where such expenditure clearly increases the economic benefits to be derived from the asset to which it relates. All other expenditure, including that incurred in order to maintain an intangible assets current level of performance, is expensed as incurred. The Company did not meet the requirements for capitalization of research and development expenses during the periods covered by this report. I. Leases: The Company applied the following practical expedients when applying IFRS 16 to leases previously classified as operating leases: • Applied a single discount rate to a portfolio of leases with reasonably similar characteristics. • Applied the exemption not to recognize right-of-use assets and liabilities for leases with less than 12 months of lease term remaining as of the date of initial application and do not contain a purchase option. • Applied the practical expedient provided by the standard to recognize right-of-use assets equal to the lease liability upon initial application. Under IFRS 16, the Company recognizes right-of-use assets and lease liabilities for most leases. The Company adopted IFRS 16 using the modified retrospective approach, with recognition of transitional adjustments on the date of initial application (January 1, 2019), without restatement of comparative figures. On initial application of IFRS 16, the Company recognized right-of-use assets and lease liabilities in relation to leases of office facilities and motor vehicles, which had previously been classified as operating leases. The lease liabilities were measured at the present value of the remaining lease payments, discounted using the Company’s incremental borrowing rate as at January 1, 2019. The Company’s incremental borrowing rate is the rate at which a similar borrowing could be obtained from an independent creditor under comparable terms and conditions. The weighted-average rate applied was 4.5%. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments. Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any accumulated impairment losses, and adjusted for any re-measurement of lease liabilities. The cost of right-of-use assets comprises the amount of the initial measurement of the lease liability; lease payments made at or before the commencement date less any lease incentives received; and initial direct costs incurred. The recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option that is reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. Lease term: The term of a lease is determined as the non-cancellable period for which a lessee has the right to use an underlying asset, together with both periods covered by an option to extend the lease if the lessee is reasonably certain to exercise that option periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option. J. Share-based payment: The Company has recognized share-based payment transactions, inter alia, for the purchase of goods or services. These transactions include transactions with employees and non-employee parties that will be settled in the Company's equity instruments, such as shares or stock options, or that will be settled in cash based on the price or value of the Company's equity instruments, and transactions that allow the Company to choose between cash in cash and disposal in the company's equity instruments. In the case of share-based payment transactions for employees disposed of in equity instruments, the value of the benefit is measured at the time of grant with respect to the fair value of the equity instruments granted. With respect to share-based payment transactions for non-employee parties settled in equity instruments, the value of the transaction is measured with respect to the fair value of the goods and/ or services received. If the Company is unable to reliably measure the fair value of the goods or services received, their fair value is measured with respect to the fair value of the equity instruments granted. In the case of share-based payment transactions that are settled in cash, the value of the benefit is presented as a liability, which is measured at fair value at the end of each reporting period and at the date of settlement. The benefit value of share-based payment transactions is recognized in profit or loss, unless the expense is included in the cost of an asset, against a capital fund over the vesting period based on the best estimate obtainable of the number of equity instruments expected to mature. When the Company received services in exchange for a payment granted based on the Company's equity instruments, it is a share-based payment transaction that is settled on equity instruments, so that an expense is recognized in profit or loss. When changes are made to a share-based payment plan, the Company recognizes the effects of changes that increase the total fair value of the plan during the remaining vesting period. K. Transactions with related parties: An asset transferred to the Company by its related parties is presented in the Company's financial statements at its fair value at the date of the transfer. Any difference between the amount of consideration determined for the property and its fair value was recognized in equity. An asset transferred from the Company to its related parties is deducted from the Company's financial statements at its fair value at the date of the transfer. The difference between the fair value of the property and the book value at the date of transfer is recognized in profit or loss and the difference between the amount of consideration determined for the property at the time of transfer and its fair value is recognized in equity. When the Company's liability to a third party, in whole or in part, is taken by a related party, the liability is deducted from the Company's financial statements at fair value at the date of settlement when the difference between the book value of the liability and the fair value at the date of disposal is recognized in profit or loss. The obligation at the time of settlement and the amount of consideration is determined by a capital seller. L. Loss per share: Loss per share is calculated by dividing the net loss attributed to the Company's shareholders by the number of weighted ordinary shares that exist during the period. The basic loss per share includes only shares that actually exist during the period. Potential ordinary shares (convertible securities such as convertible bonds, warrants and employee stock options) are included only in the calculation of diluted earnings per share to the extent that their effect dilutes loss per share by converting them to decreases earnings per share or increases losses per share. In addition, potential ordinary shares converted during the period are included in the diluted earnings per share only up to the date of conversion, and from that date are included in the basic loss per share. M. IIA grants: A grant from the “Israel Innovation Authority” (or “IIA”) received for research and development activities, for which the Company undertook making royalties’ payments to the government contingent on making future sales resulting from such grant financing, was treated as a loan that could be forgiven and recognized as a reimbursement of related research expenses or development costs. The grant was recognized as a liability in the financial statements. Unless there is reasonable assurance that the Company will meet the conditions for the forgiveness of the loan, then it has been recognized as a government grant. When the liability to the government does not bear market interest, the liability was recognized at its fair value in accordance with the market interest rate at the time the grant was received. The difference between the consideration received and the liability recognized in the statement of financial position at the time of receiving the grant was treated as a government grant and recognized as a reimbursement of research expenses or as a reduction of development costs capitalized as the case maybe. Repayment of the liability to the government is reviewed every reporting period, with changes in the liability resulting from a change in the expected royalties recognized in profit or loss. N. Credit costs: The Company recognized credit costs as an expense in the period of formation, except in cases where they can be directly attributed to the acquisition, construction or production of eligible assets, and in such cases these costs were capitalized as part of the cost of those assets. The Company capitalized credit costs when exits were formed in respect of the property, credit costs were formed, and the activities required to prepare the property for its intended use or sale were carried out. The Company stops capitalizing credit costs when substantially all the activities required to prepare the eligible asset for its intended use or sale have been completed. During prolonged periods in which the active development of a qualifying asset has stopped, the Company delayed the capitalization of credit costs. O. Capital instrument: Any contract that classifies a residual right in a company's assets after deducting all its liabilities is classified as an equity instrument. Costs directly related to the issuance of an equity instrument are presented in equity less the issue. Rights, options, or warrants offered in proportion to all existing owners of the same type of shares for the purchase of a fixed number of shares for a fixed amount in any currency have been classified as an equity instrument. P. Warrants: Equity Warrants: Receipts in respect of warrants for the purchase of shares of the company/ subsidiary, which give the holder the right to purchase a fixed number of equity instrument (e.g., ordinary shares) in exchange for a fixed amount of cash, are classified as equity. Financial liability: Receipts in respect of warrants for the purchase of shares of the Company, which give the holder the right to purchase a fixed number of ordinary shares in exchange for a variable amount, including when the exercise of the warrants is linked to any index or foreign currency, are classified as liabilities (See also Note 15). Q. Fair value measurement: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: 1. In the principal market for the asset or liability, or 2. In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible to the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. The Company measures the following balances according to Fair value: financial lability warrants. Classification of fair value hierarchy The financial instruments presented in the statement of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value. The classification of an item into the below levels is based on the lowest level of the inputs used that has a significant effect on the fair value measurement of the item. Transfers of items between levels are recognized in the period they occur: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly. Level 3 - Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). R. Financial instruments: Financial assets: The Company classifies its financial assets into the following categories, based on the business model for managing the financial asset and its contractual cash flow characteristics. The Company's accounting policy for the relevant category is as follows: Amortized cost: These assets arise principally from the services rendered to customers (e.g. trade receivables), but also incorporate other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value plus transaction costs that are directly attributable to their acquisition or issue and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment. Impairment provisions for trade receivables are recognized based. On the simplified approach within IFRS 9 using a provision matrix in the determination of the lifetime expected credit losses. During this process the probability of the non-payment of the trade receivables is assessed. This probability is then multiplied by the amount of the expected loss arising from default to determine the lifetime expected credit loss for the trade receivables. For trade receivables, which are reported net, such provisions are recorded in a separate provision account with the loss being recognized within general and administrative expenses in the consolidated statements of comprehensive income. On assessment that the trade receivable will not be collectable, the gross carrying value of the asset is written off against the associated provision. For this purpose, the Company relied on historical data that includes debt settlement, failure rate of lost debt to each company in the group in the period of the last 5 years up to the date of measurement. The Company updates the impairment provision at the end of each reporting period, and the change in the provision as it exists is recognized as a gain or loss from an impairment loss or loss. At the end of each reporting period the Company assesses whether an asset has been impaired due to credit risk (i.e. if an event has occurred that has a detrimental effect on the future cash flows of the estimated asset). Evidence that a property is defective includes for example a significant financial difficulty of the debtor. The Company writes off the value in the gross books of a financial asset, in whole or in part, when the Company has no reasonable expectation of the return of the asset, for example when the debtor enters into a foreclosure or bankruptcy proceeding. Fair value: All other financial assets, including debt instruments when first recognized at fair value through profit or loss to eliminate or significantly reduce inconsistency in measurement or recognition, were first measured at fair value, and changes in fair value after initial recognition were recognized in profit or loss. Transaction costs that were directly attributed to these assets were recognized in profit or loss at the time they were incurred. Reclassification of measurement groups after initial recognition is not possible unless the Company changes its business model for managing financial assets. Financial liabilities: The Company's accounting policy for its financial liabilities is as follows: • Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive loss. • Amortized cost: other financial liabilities, including bank borrowings, loans from bank, trade payables, loan from major shareholder, leases and financial liability from government grants, are initially recognized at fair value less any transaction costs directly attributable to the issue of the instrument. Such interest-bearing liabilities are subsequently measured at amortized cost using the effective interest method, which ensures that any interest expense over the period is at a constant interest rate on the balance of the liability carried in the statement of financial position. Interest expense in this context includes initial transaction costs, as well as any interest or coupon payable while the liability is outstanding. De-recognition: ● Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive income. ● Financial Liabilities - the Company derecognizes financial liability when its contractual obligations are discharged or cancelled or expire. Impairment of financial assets: The Company assesses at the end of each reporting period whether there is any objective evidence of impairment of a financial asset as follows. Financial assets carried at amortized cost: there is objective evidence of impairment of other accounts receivable if one or more events have occurred after the initial recognition of the asset and that loss event has an impact on the estimated future cash flows. Evidence of impairment may include indications that the debtor is experiencing financial difficulties, including liquidity difficulty and default in interest or principal payments. Write-off policy: The Company writes off its financial assets if any of the following occur: 1. Inability to locate the debtor. 2. Discharge of the debt in a bankruptcy. 3. It is determined that the efforts to collect the debt are no longer cost effective given the size of receivable. S. Issue of a unit of financial instruments: The issue of a unit of financial instruments like a financial liability (e.g., a loan) and free-standing derivative (e.g. warrants) involves the allocation of the proceeds received (before issue expenses) to the instruments issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit. T. Impairment of non-financial assets: Other intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment l

MDA AGREEMENT

MDA AGREEMENT	12 Months Ended
	Dec. 31, 2023
Mda Agreemet [Abstract]
MDA AGREEMET:	NOTE 3 - MDA AGREEMET: In August 2023, the Company announced a $60 million transaction with MDA LTD. (“MDA”) (TSX: MDA), a leading provider of advanced technology and services to the rapidly expanding global space industry (the “MDA Agreement”). The MDA Agreement establishes cooperation between the Company and MDA to utilize the Company’s digital payload chip-based technology to advanced digital satellite payloads. The Company has decided to focus its space business on being a technology provider to satellite payload design companies offering its unique digital multi beam forming and beam-hopping on-board-processing radiation hardening chipsets. The MDA Agreement is a combination of a $40 million share purchase agreement selling the Company’s holdings in SatixFy Space Systems LTD, one of our UK based subsidiaries, to MDA as well as an additional $20 million in advanced payments under new commercial agreements which includes the previous $10 million advanced payment made in June 2023 to be applied to future orders of space grade chips. SatixFy Space Systems was the Company’s satellite payload subsidiary expert in the development of digital satellite payloads systems and subsystems, including digital beam forming antennas and on-board processing digital payloads. In October 2023, the Company announced the completion of the MDA Agreement. In connection with the closing, the Company and/ or certain of its affiliates, entered into certain agreements with MDA and/ or certain of its affiliates as contemplated by the MDA Agreement and described including but not limited to a Non-Compete Agreement, Master Purchase Agreement, Investor Rights Agreement, License Agreement and Escrow Service Agreements. The $40 million consideration as part of the share purchase agreement is comprised of $37 million Promissory Notes, converted from Inter-Company balance due to the Company's subsidiaries and $3 million to be paid to the Company in consideration for the Shares of SatixFy Space Systems LTD, of which, $1 million was paid at closing while the remaining $2 million will be to be received after eighteen month from closing upon satisfaction of the provided reps and warranties by the Company (“Hold- Back”). The Promissory Notes are settled as follows: $17 million were paid at closing and the remaining $20 million are to be paid over seven monthly instalments of $2.85 million each. As part of the MDA agreements, SatixFy UK Limited and MDA entered into a Master Purchase Agreement (the “Master Purchase Agreement”) at the closing, providing for the terms of orders of the Company’s space grade chips, including certain prepayment, exclusivity and preferred pricing terms in respect of such chips for MDA. The Master Purchase Agreement is a continuation of a Pricing and Pre-Purchase Agreement entered into on January 27, 2022 between the Company and MDA (“the Pre-Purchase Agreement”), under which MDA has already paid $10 million as was amended in June and September 2023 according to which MDA paid an additional $15 million and intends to pay the remaining $5 million during 2024 (“Pre-Purchase Amount”). Under the Master Purchase Agreement, in the event that MDA determines that it no longer requires the Company's product, or that it does not purchase product having an aggregate purchase price equal to the Pre-Purchase Amount by the date that is 48 months from the date that the Pre-Purchase Agreement was originally executed by the Parties, or that MDA terminates the agreement – the Company will pay MDA any positive difference between the Pre-Purchase Amount and the aggregate purchase price of the products purchased and accepted by MDA, together with 12% interest per annum, applied from the date of execution of the original pre-purchase agreement. As the Company does not have an unconditional right to avoid delivering cash to MDA, the Pre-Purchase Amount was accounted for as a financial liability and accumulated interest.

CONTRACT ASSETS

CONTRACT ASSETS	12 Months Ended
	Dec. 31, 2023
Contract assets [abstract]
CONTRACT ASSETS	NOTE 4 - CONTRACT ASSETS: December 31, 2023 December 31, 2022 Related parties (See Note 14) - $ 1,679 Other trade receivables 4,091 3,356 $ 4,091 $ 5,035 December 31, 2023 December 31, 2022 Balance at the beginning of the year 5,035 6,015 Revenue recognition in the period, net 643 (426 ) Provision (1,876 ) - Currency translation adjustments 289 (554 ) Balance at the End of the year $ 4,091 $ 5,035

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2023
Classes of current inventories [abstract]
INVENTORY	NOTE 5 - INVENTORY: Inventories are stated at the lower of cost or market, computed using the FIFO method. Following is a breakdown of the Company’s inventory: December 31, 2023 December 31, 2022 Raw materials $ 1,397 $ 817 Finished goods inventory 78 14 $ 1,475 $ 831

LEASE LIABILITIES AND RIGHT OF

LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET	12 Months Ended
	Dec. 31, 2023
LEASE LIABILITIES AND RIGHT OF USE ASSETS
LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET	NOTE 6 - LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET: The Company has lease agreements that include leases of buildings and vehicles that are used for the purpose of carrying out the Company's ongoing activities. The lease agreements of the buildings are for a period of up to 5 years. While the lease agreements of the vehicles are up to 3 years. The Company leases the offices of its corporate headquarters located in Rehovot, Israel. The lease for this office expires in May 2028. The Company also leases an office in the UK in Farnborough. The office in the UK serves as a research and development and operations centers. The lease agreement for the office of Farnborough expires in October 2026. The Company also leases an office in Sofia Bulgaria, where it employs its antenna development team. The lease agreement for the office in Bulgaria included two agreements which will expire in May 2024. The Company also leases an office in Pennsylvania USA that serve as a research and development center. The lease agreement for the office in Pennsylvania expires in March 2025. a. Extension and cancellation options: The Company has lease agreements that include extension options. These options give the Company flexibility in managing the lease transactions and adjustment to the Company's business needs. The Company exercises significant discretion in examining whether it is reasonably certain that the extension options will be exercised. The Company included as part of the lease period the exercise of the extension options existing in the agreements, for assets in which the Company expects to exercise the option. There are no extension options in vehicle lease agreements. The Company also has certain leases of office facilities with lease terms of 12 months or less. The Company applies the exemption to the recognition of 'short-term leases' to these leases. b. The following is a list of the carried values of the lease assets recognized and the transactions during the period: Buildings Cars Total Cost January 1, 2023 4,918 155 5,073 Additions 662 103 765 Disposals- Sale of SSS (1,741 ) (74 ) (1,815 ) December 31, 2023 3,839 184 4,023 Accumulated Depreciation January 1, 2023 (2,256 ) (23 ) (2,279 ) Additions (916 ) (83 ) (999 ) Disposals- Sale of SSS 1,454 36 1,490 December 31, 2023 (1,718 ) (70 ) (1,788 ) Net Book value December 31, 2023 2,121 114 2,235 Buildings Cars Total Cost January 1, 2022 5,294 82 5,376 Additions 434 156 590 Disposals (810 ) (83 ) (893 ) December 31, 2022 4,918 155 5,073 Accumulated Depreciation January 1, 2022 (2,155 ) (74 ) (2,229 ) Additions (911 ) (32 ) (943 ) Disposals 810 83 893 December 31, 2022 (2,256 ) (23 ) (2,279 ) Net Book value December 31, 2022 2,662 132 2,794 c. Details regarding lease transactions: For the year ended December 31, 2023 December 31, 2022 Interest expenses in respect of lease liabilities 337 393 Lease principal payments during the year 927 1,029

INVESTMENT IN JET-TALK

INVESTMENT IN JET-TALK	12 Months Ended
	Dec. 31, 2023
INVESTMENT IN JET TALK:
INVESTMENT IN JET-TALK	NOTE 7 - INVESTMENT IN JET-TALK: In March 2018 Satixfy UK Limited (the "UK subsidiary") signed a Joint Venture agreement with ST Electronics (Satcom & Sensor Systems) Pte LTD ("STE") according to which STE invested $20 million in the joint venture while the UK subsidiary had committed to provide to Jet Talk Limited (“Jet Talk”) with future development services of a an electronically steerable Panel Antenna Array (“PAA”) and supporting modem, exclusive marketing rights for the commercial aviation market, technical skills, staff expertise, R&D facilities and exclusive, royalty-free, world-wide, perpetual, non-transferable, irrevocable license to use and commercially exploit the Company's intellectual property for the purposes of development, production, sales and marketing of satellite antenna systems. As part of the Company’s commitment to the future development services to Jet Talk, the Company signed two development agreements to provide an electronically steerable Panel Antenna Array (“PAA”) and supporting modem for a total consideration of $13 million to be provided during 2018 through 2023. Accordingly, the joint venture company, Jet Talk, was incorporated in England and Wale and is 51% held by the UK subsidiary and 49% held by STE. Jet Talk developed the industry’s first Aero In Flight Connectivity (IFC) solution, delivering simultaneous high bit rate Internet and TV channels over current satellites. Although the Company holds the majority of voting rights (51%), STE in fact participates in significant financial and operational decisions of Jet Talk made during the ordinary course of business including appointing a CEO, directing R&D activities, directing marketing activities while utilizing its East Asia business connections and its control over the Company’s financing activity. In view of the analysis of the relevant activities of the investee and the examination of the Company's ability to direct these operations, the Company concluded that it has no influence over all of the investee’s most relevant operations and hence the Company has no control over the investee. Consequently, the investment in Jet Talk is accounted for in accordance with the equity method and assessed under IFRS 28, Investments in Associates and Joint ventures. Condensed financial information of Jet-Talk: December 31, 2023 December 31, 2022 December 31, 2021 Net loss Company share 442 705 3,722 Company's share in the loss of a company accounted by equity method, net 226 360 1,898

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2023
PROPERTY, PLANT AND EQUIPMENT, NET
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 8 - PROPERTY, PLANT AND EQUIPMENT, NET: Property, plant and equipment consist of the following as of December 31, 2023, and 2022: Computers Leasehold improvements Furniture Machinery and Equipment Total Cost January 1, 2023 1,092 600 347 1,043 3,082 Additions 113 52 5 65 235 Disposal -SSS sale (13 ) (119 ) - (53 ) (185 ) December 31, 2023 1,192 533 352 1,055 3,132 Accumulated Depreciation January 1, 2023 (832 ) (262 ) (162 ) (183 ) (1,439 ) Additions (156 ) (62 ) (29 ) (61 ) (308 ) Disposal -SSS sale 1 34 - - 35 December 31, 2023 (987 ) (290 ) (191 ) (244 ) (1,712 ) Net Book value December 31,2023 205 243 161 811 1,420 Computers Leasehold improvements Furniture Machinery and Equipment Total Cost January 1, 2022 956 477 345 414 2,192 Additions 136 123 2 629 890 December 31, 2022 1,092 600 347 1,043 3,082 Accumulated Depreciation January 1, 2022 (714 ) (212 ) (138 ) (156 ) (1,220 ) Additions (118 ) (50 ) (24 ) (27 ) (219 ) December 31, 2022 (832 ) (262 ) (162 ) (183 ) (1,439 ) Net Book value December 31,2022 260 338 185 860 1,643 Depreciation expenses totaled $308 and $219 the year ended December 31, 2023 and December 31, 2022, respectively.

CONTRACT LIABILITIES

CONTRACT LIABILITIES	12 Months Ended
	Dec. 31, 2023
Contract liabilities [abstract]
CONTRACT LIABILITIES:	NOTE 9 - CONTRACT LIABILITIES: Contract liabilities fully reflect the remaining amount to be recognized for each cut-off period in respect of certain contracts with customers. December 31, 2023 December 31, 2022 Balance at the beginning of the year 622 475 Expenses recognition in the period, net 819 540 Currency translation adjustments 279 (393 ) Balance at the end of the year $ 1,720 $ 622

OTHER ACCOUNTS PAYABLE AND ACCR

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2023
Other Accounts Payable And Accrued Expenses [Abstract]
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 10 - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES: December 31, 2023 December 31, 2022 Liabilities in respect of employees, wages and institutions in respect of wages 2,584 3,023 Accrued expenses 6,849 4,607 Liabilities to government institutions due to grants received 136 161 Tax accrual 122 - Government departments and agencies 13 52 9,704 7,843

LIABILITIES FOR EMPLOYEE SEVERA

LIABILITIES FOR EMPLOYEE SEVERANCE PAY, NET	12 Months Ended
	Dec. 31, 2023
Restructuring And Related Activities Abstract
LIABILITIES FOR EMPLOYEE SEVERANCE PAY, NET	NOTE 11 - LIABILITIES FOR EMPLOYEE SEVERANCE PAY, NET: On May 7, 2006, an extension order in Israel came into force in the manufacturing industry (hereinafter - the “Extension Order”) which applied Section 14 of the Severance Pay Law. Thus, Israeli employees who began their work after May 7, 2006, will receive comprehensive pension insurance. The section also grants employees the right to receive, both in the event of dismissal and in the event of resignation, the component of severance pay, which has been accrued in the funds the Company has created for him/ her. On the other hand, the arrangement in Section 14 of the Israeli Severance Pay Law releases the company from the obligation to complement fund contributions if the amount accumulated in the funds does not reflect the amount of severance pay due to the employee under law. The Company applies Section 14 of the Severance Pay Law to its Israeli employees.

LONG TERM LOANS FROM FINANCIAL

LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET	12 Months Ended
	Dec. 31, 2023
LOAN FROM SHAREHOLDER
LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET	NOTE 12 - LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET : a. In July 2016, the Israeli subsidiary entered into an agreement for a bank loan (hereinafter - the “First Loan") in the amount of $2,000 for a period of 36 months, at an annual interest rate of LIBOR + 6.9%. In addition, the Company issued warrant for a period of 6 years. The warrant was exercised in July 2022 on a cashless basis to 57,659 shares. The loan was fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from, Francisco Partners, See also Note b. In May 2019 and in March 2020, the Israeli subsidiary took out a loan including two portions from a bank in the amounts of $5 million and $3 million, respectively, for a period of 36 months (hereinafter: the “Second Loan"). The Company issued warrants for a period of 10 years. Following the closing of the SPAC transaction on October 27, 2022 the Bank decided to receive the Alternative Payment instead of exercising the warrants and following that decision, the $800 Alternative Payment was paid to the Bank in February 2023. The loan was repaid in full in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e). As part of the SPAC merger (see Note 1) the bank has exercised the warrants into cash. c. In April 2020 and in September 2020 , following the COVID-19 pandemic, the Israeli subsidiary took out a five-year state-guaranteed bank loans on preferential terms bearing a yearly interest of premium plus 1.5. The loans were fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e). d. In April 2021 and in August 2021 the Company signed a $5 million and $2.3 million loan agreement, respectively, with a financial institution named Liquidity Capital II L.P. (“Liquidity”), with a repayment period of thirty (30) months. For that purpose, the Company granted to Liquidity a warrant for a period of eight (8) years, Following the closing of the SPAC transaction on October 27, 2022 the warrants were exercised on a cashless basis into 6,520 ordinary shares. The loan was fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners. See also Note 12(e). e. On February 1, 2022, the Company signed a $55 million loan agreement ("the 2022 Credit Agreement" with affiliates of a financial institution named Francisco Partners L.P. ("FP"), with a repayment period of between 2.5 to 4 years depending on the Company completing a qualified public offering within 12 months of closing. The loan beard a yearly interest of 9.5% on the outstanding balance. In the event the Company will not complete a qualified public offering during the first year, then the interest rate shall increase by 100 basis points per year beginning in year 2 up to a maximum rate of 11.5% total. As long as the Company was private, there was an ability to Pay In Kind (“PIK”) 100% of interest in year 1, 75% of interest in year 2, and 50% of interest thereafter. Once the Company completes a qualified public offering, then 100% of interest is paid in cash thereafter. Until October 27, 2022 the PIK interest of $3,988 was added to the loan balance. As consideration for the loan, the Company also issued to the lenders under the credit agreement 808,907 of its ordinary shares. Following the receipt of the proceeds from the loan, The Company repaid all of its existing borrowings in an amount of $19.1 million, including a $5.3 million loan from a shareholder and $13.8 million of loans from financial institutions. On April 23, 2023, the Company and FP. entered into a waiver and amendment to the 2022 Credit Agreement whereby FP, (i) provided a waiver of certain defaults or potential defaults, (ii) permitted the Company to make its interest payments for 2023 on a pay-in-kind basis if its cash balance is less than $12.5 million, (iii) temporarily reduced the Company’s minimum cash requirement from $10 million to $8 million and $7 million for the months of April and May 2023, respectively, and thereafter to $10 million, in each case plus an amount sufficient to cover its and its subsidiaries’ accounts payable that are past 60 days due, (iv) increased the interest rate of the loan to Secured Overnight Financing Rate (“SOFR”) + 9.50% (with a 3% SOFR floor) and (v) provided for certain additional reporting obligations by the Company. In June 2023 the Company and FP entered into an amendment which provides, among other things, upon the Company’s receipt of a $10 million prepayment as part of the MDA Agreement (see Note 3), interest payable thereunder will be added to the principal of the term loan on a “pay in kind” basis through June 28, 2024,the payments made in connection with the pre-purchase agreement will not be applied to repay debt under the 2022 Credit Agreement, a limited waiver, subject to certain conditions, of the $10 million minimum cash requirement liquidity covenant therein, and following closing of the MDA Agreement, a reduced interest rate and the issuance by the Company of 5,100,000 ordinary shares, of which 1,000,000 Price Adjustment S hares were issued in a private placement within 30 days, which shares will be subject to substantially the same terms governing the Price Adjustment Shares (See Note 15(g)) previously issued in connection with the business combination with Endurance. On October 31, 2023, the Company entered into another Amendment to the 2022 Credit Agreement, whereby the lenders provided their consent to the MDA agreements and to wave financial covenants which were associated with the 2022 Credit Agreement. This amendment was accounted for as an extinguishment of the loan. In reaching this conclusion, the Company considered the impact of consecutive modifications of the loan throughout 2023; also, the Company noted that the issuance of ordinary shares in terms similar to the ones governing the Price Adjustment Shares gives rise to a substantial qualitative change in the 2022 Credit Agreement. As such, the Company accounted for the modified loan as a derecognition of the existing loan and recognition of the modified loan at fair value with any differences as finance expenses. The finance incomes resulted from the modification amounted to $ million. For the year ended December 31 2023 2022 Long term loans from financial institutions 59,792 54,926 Financial covenants: According to the amended terms of the 2022 Credit Agreement, the Company’s cash must be held in deposit accounts subject to a security interest in favor of the Agent for the benefit of the lenders. In addition, the Company must meet affirmative and negative covenants customary for a financing of this type, including but not limited to, limitations on indebtedness, restricted payments, dividends, transactions with affiliates, investments, lines, acquisitions, and asset sales. The FP loan is guaranteed on a senior secured basis by the Company and its subsidiaries, subject to customary exceptions. The Company complies with the covenants.

LOAN FROM SHAREHOLDER

LOAN FROM SHAREHOLDER	12 Months Ended
	Dec. 31, 2023
Disclosure Of Loan From Shareholder Abstract
LOAN FROM SHAREHOLDER	NOTE 13 - LOAN FROM SHAREHOLDER: In March 2020 Satixfy UK signed a $5 million loan agreement with an existing shareholder of the company, with a repayment period of thirty-six (36) months. As part of the loan agreement, the Company granted the shareholder warrants, the warrants were classified to equity and were first booked at fair value. The Company took out a $5 million "key personnel" insurance policy as a guarantee for the loan on the Company's former CEO, Mr. Yoel Gat. After the passing of Mr. Yoel Gat (see note 14) in April 2022, the Company received $5.4 million as compensation under this life insurance policy. The loan was fully repaid in February 2022 using proceeds that were received from a new loan that the Company received from Francisco Partners see also Note12 (e).

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2023
RELATED PARTIES:
RELATED PARTIES	NOTE 14 - RELATED PARTIES: The Company’s policy is to enter into transactions with related parties on terms that are on the whole no less favorable to it than those that would be available from unaffiliated parties at arm’s length. Based on its experience in the business sectors in which it operates and the terms of the transactions with unaffiliated third parties, the Company believes that all of the transactions described below met this policy standard at the time they occurred. On May 4, 2017, the Company's Board of Directors approved the execution of a management and consulting services agreements with Ilan Gat Engineers LTD. (hereinafter: "Ilan Gat"), an entity which was controlled by Mr. Yoel Gat, the former CEO and a significant shareholder in the Company. According to this agreement, as of 2018, the management fees were paid to Ilan Gat, which consists of a monthly management fee of $50 and reimbursement of other monthly expenses for the services of Yoel Gat and Simona Gat, the former President and former COO of the Company. In November 2019 the Company’s board of directors approved a retroactive update of the monthly management fee starting in January 2019 to the amount of $100 and reimbursement of other monthly expenses. In January 2021 the Company’s board of directors approved an update of the monthly management fee starting in January 2021 to the amount of $110 and reimbursement of other monthly expenses and a yearly bonus of 0.67% for Yoel Gat’s services and 0.67% for Simona Gat’s services out of the incremental year to year growth in Equity in the consolidated financial statements of the Company effective 2021 and Annual Bonus of 0.67% for Yoel Gat’s services and 0.67% for Simona Gat’s services out of the incremental year to year growth in revenues of the Company each year effective 2021. On December 24 th th On April 8, 2022 Mr. Yoel Gat, the Company’s former CEO, Chairman and founder passed away due to fatal illness and his entire holdings were inherited by Ms. Simona Gat. On April 30, 2023, SatixFy Communications LTD. and Ilan Gat LTD. entered into a Separation Agreement pursuant to which Ms. Gat resigned from all positions at the Company and its subsidiaries, including serving as the President of the Company. Effective May 1, 2023, she instead began serving as an observer on the board of directors of the Company. The Company agreed to pay Ms. Gat compensation consisting of (i) five monthly payments in the gross sum of $55,000 plus VAT from May through September 2023; (ii) one monthly payment of $110,000 plus VAT in October 2023, totaling in the aggregate, $385,000 plus VAT; and (iii) other customary terms and conditions. The Company and RaySat LTD. (“RaySat”), an entity organized under the laws of the State of Israel and controlled by Mr. Yoav Leibovitch, our Chairman of the board of directors and one of our significant shareholders, are parties to a Services Agreement effective as of January 1, 2013 (as amended as of June 27, 2017, September 6, 2020, January 4, 2021 and February 24, 2022). Pursuant to this agreement, Mr. Yoav Leibovitch provides financial management, business development, presidential and management services to the Company and its subsidiaries. On September 15, 2022, the Company’s board approved an amendment, which was approved by The Company’s shareholders on September 28, 2022, to Mr. Leibovitch’s compensation under this agreement to (i) grant Mr. Leibovitch a $2 million success bonus payable upon the Closing of the Business Combination, (ii) increase Mr. Leibovitch’s monthly fee for services provided to $100,000 per month, effective as of October 1, 2022, increase Mr. Leibovitch’s yearly bonus such that the yearly bonus shall be 2% of the incremental year-over-year growth of the shareholders’ equity in the consolidated financial statements of the Company and increase Mr. Leibovitch’s annual bonus such that the annual bonus shall be 2% of the incremental year- over-year growth of revenues in the consolidated financial statements of the Company. On October 19, 2023, upon recommendation of the Company’s board and compensation committee, our shareholders approved a one-time special success bonus of up to $1 million in the aggregate to our Executive Chairman of the Board, Mr. Yoav Leibovitch, in connection with the MDA Agreement (See note 3). The MDA bonus is to be paid in nine installments. Each of the special success bonus amounts relates to proceeds we have received and expect to receive with respect to the MDA Agreement during the relevant month. The MDA bonus shall not be paid if for any reason whatsoever, whether due to default by the Company or otherwise, we do not actually receive the relevant proceeds with respect to the MDA Agreement. On February 6, 2018 and on February 14, 2020 the Company signed three development agreements with Jet Talk to provide an electronically steerable Panel Antenna Array (“PAA”) and supporting modem for a total consideration of $32,000 to be provided during 2018 through 2023. (See also Note 7). Transactions with related parties: For the year ended December 31 2023 2022 Revenues from ST Engineering iDirect (“iDirect”) (*) 2,065 489 (*) iDirect is a shareholder of the Company and after SPAC transaction iDirect is no longer a related party due to their decreased holding. For the year ended December 31, 2023: Name Position Scope of Position Holding Rate Salary, bonuses and related expenses Expected Bonus Share- Based Payments Nir Barkan Acting CEO Full Time 0.25% 303 160 129 Ilan Gat (Simona Gat) Former president and COO Full Time 19.47% 605 - 39 Raysat (Yoav Leibovitch) Chairman Full Time 26.35% 1,750 450 39 For the year ended December 31, 2022: Name Position Scope of Position Holding Rate Salary, bonuses and related expenses Expected Bonus Share- Based Payments Ilan Gat (Simona Gat) President and COO Full Time 19.8% 660 40 39 Raysat (Yoav Leibovitch) Chairman Full Time 27.04% 5,065 60 39 Outstanding balances with related parties: For the year ended December 31 2023 2022 Assets Contract assets (Jet Talk) - 1,679 Jet Talk 75 157 Total Assets 75 1,836 Labilities Raysat Israel LTD. 550 160 Ilan Gat Engineers LTD - 95 Former CEO - 100 Current CEO 190 - Jet Talk - 53 Total Liabilities 740 408

FINANCIAL INSTRUMENTS - RISK MA

FINANCIAL INSTRUMENTS - RISK MANAGEMENT	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS – RISK MANAGEMENT	NOTE 15 - FINANCIAL INSTRUMENTS – RISK MANAGEMENT: The Company’s activities expose it to various financial risks, such as market risk, including currency risk, credit risk and liquidity risk. The Company’s overall risk management plan focuses on minimizing possible adverse effects on the Company’s financial performance. Risk management is performed by the CFO, which includes examining certain exposures to risks, such as exchange rate risk, credit risk. In 2023 and 2022, the Company did not use derivative financial instruments to hedge its operations. Credit risk: Credit risk is created when the failure of parties against the fulfillment of their obligations may reduce the amount of future cash flows from the financial assets held by the Company to the balance sheet date. The Company’s main financial assets are cash and cash equivalents, customers and other receivables, and represent the Company’s maximum exposure to credit risks in connection with its financial assets. The Company holds cash in large financial institutions. The par value of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the time of reporting was: December 31, 2023 December 31, 2022 Cash 13,979 11,934 Trade accounts receivables 2,260 1,295 Other accounts receivable 2,053 2,166 Promissory Notes 20,000 - Other long term receivables 2,000 - FPA - 40,852 Contract assets 4,091 5,035 Total 44,383 61,282 a. Currency risk: Currency risk is the risk that the value of financial instruments will be affected by changes in exchange rates. Currency risk is created when future commercial transactions and recognized assets and liabilities are denominated in a currency other than the Company’s operating currency. The company is exposed to foreign currency risk resulting from exposures to various currencies, mainly in relation to the New Israeli Shekel ("NIS”), (“EUR”) (“GBP”). The Company's hedging As of the balance sheet date, the Group’s exposure to currencies as follows: December 31, 2023 NIS EUR GBP USD Total Assets: Cash and cash equivalents 1,120 1,372 235 11,252 13,979 Trade receivables - 55 - 2,205 2,260 Prepaid expenses and other account receivables 2,036 17 2,053 Promissory Notes - - - 20,000 20,000 Other long-term receivables - - - 2,000 2,000 Contract Assets - - 128 3,963 4,091 1,120 3,463 363 39,437 44,383 Liabilities: Current liabilities: Current maturities long-term loans - - - - - Liabilities in respect of leases-ST (469 ) - (144 ) (26 ) (639 ) Advanced payments from MDA against future orders - - - (28,138 ) (28,138 ) Trade payables (479 ) (368 ) (284 ) (247 ) (1,378 ) Payables and credit balances (896 ) (618 ) (415 ) (5,942 ) (7,871 ) (1,844 ) (986 ) (843 ) (34,535 ) (38,026 ) Non-current liabilities: Liability for IIA Royalties (1,196 ) - - - (1,196 ) Liabilities in respect of leases-LT (1,558 ) - (495 ) (14 ) (2,067 ) Long term loans from banks - - - (59,792 ) (59,792 ) Net balances (3,478 ) 2,477 (975 ) (54,722 ) (56,698 ) b. Sensitivity analysis: December 31, 2022 NIS EUR GBP USD Total Assets: Cash and cash equivalents 1,281 640 607 9,406 11,934 Trade receivables - 187 804 304 1,295 Prepaid expenses and other - 2,149 - 17 2,166 Derivatives FPA - - - 40,852 40,852 Contract Assets - - 3,720 1,315 5,035 1,281 2,976 5,131 51,894 61,282 Liabilities: Current liabilities: Current maturities long-term loans - - - - - Liabilities in respect of leases-ST (430 ) - (591 ) - (1,021 ) Trade payables (614 ) (324 ) (433 ) (88 ) (1,459 ) Payables and credit balances (2,644 ) (942 ) (721 ) (3,322 ) (7,629 ) (3,688 ) (1,266 ) (1,745 ) (3,410 ) (10,109 ) Non-current liabilities: Liability for IIA Royalties (1,107 ) - - - (1,107 ) Liabilities in respect of leases-LT (1,830 ) - (450 ) - (2,280 ) Long term loans from banks - - - (54,926 ) (54,926 ) Net balances (5,344 ) 1,710 2,936 (6,442 ) (7,140 ) A 10% strengthening of the dollar against the following currencies would have resulted in an increase (decrease) in the equity and profit and loss in the amounts presented below. This analysis assumes that all other variables, and especially interest rates, remain constant. A 10% weakening of the currency against the relevant currencies will have the same effect in the opposite direction on equity and profit and loss. December 31, 2023 December 31, 2022 Linked to NIS (3,478 ) (5,344 ) 10 % 10 % (348 ) (534 ) Linked to EUR 2,477 1,710 10 % 10 % 248 170 Linked to GBP (975 ) 2,936 10 % 10 % (97 ) 294 c. Liquidity risks: Liquidity risks arise from the management of the Group’s working capital as well as from the financing expenses and principal repayments of the Group’s debt instruments. Liquidity risk is the risk that the Group will find it difficult to meet obligations related to financial liabilities. The following is an analysis of the contractual maturities of financial liabilities in accordance with nominal values for settlement. Based on the earliest time the company will be required to pay: December 31, 2023 Within 30 days 1-12 Months 1-5 Years Total Liabilities in respect of leases-ST 172 467 - 639 Trade payables 258 1,120 - 1,378 Promissory Notes - 20,000 - 20,000 Other long term receivables - - 2,000 2,000 Payables to related parties - 740 - 740 Other Accounts Payable 1,581 6,290 - 7,871 Long term loans from banks, net - - 68,020 68,020 Liabilities in respect of leases-LT - - 2,067 2,067 Advanced payments from MDA against future orders - - (28,138 ) (28,138 ) Liability for IIA Royalties - - (1,107 ) (1,107 ) Derivatives Liabilities - - (114 ) (114 ) Total 2,011 28,617 42,728 73,356 December 31, 2022 Within 30 days 1-12 Months 1-5 Years Total Liabilities in respect of leases-ST 269 752 - 1,021 Trade payables 251 1,209 - 1,460 Payables to related parties - - - - Other Accounts Payable 3,534 4,309 - 7,843 Long term loans from banks, net - - 77,543 77,543 Liabilities in respect of leases-LT - - 2,280 2,280 Loan from Shareholder - - - - Derivatives Liabilities - - 20,305 20,305 Total 4,054 6,270 100,128 110,452 d Fair value of financial instruments measured at fair value on a periodic basis: Level December 31, 2023 December 31, 2022 Financial Liabilities: Warrants 3 - - SPAC Public Warrant 1 - 286 SPAC Private Warrant 2 - 121 Advanced payments from MDA against future orders 3 28,138 - Price Adjustment shares 3 114 19,898 Total 28,252 20,305 e. Classification of financial instruments by fair value hierarchy: The financial instruments measured in the balance sheet at fair value are classified, according to groups with similar characteristics, into a fair value ranking as follows, determined in accordance with the data source used to determine the fair value: Level 1: Quoted prices (without adjustments) in an active market of identical assets and liabilities. Level 2: Non-quoted prices data included in Level 1 which can be viewed directly or indirectly. Level 3: Data that are not based on viewable market information (assessment techniques without the use of viewable market data). As mentioned in Note 12, the warrants granted to the bank and to Liquidity are derivative financial liablities and accordingly measured at each balance date at fair value through profit or loss. All warrants balance as of December 31, 2021 Warrants Balance at January 1, 2022 1,392 Exercise of warrants to shares (397 ) Exercise of warrants to cash (adjustment to other accounts payables) (800 ) Changes in fair value recognized in finance expenses (195 ) Balance at December 31, 2022 - Exercise of warrants to shares - Exercise of warrants to cash (adjustment to other accounts payables) - Changes in fair value recognized in finance expenses - Balance at December 31, 2023 - f. SPAC warrants: As part of the Business Combination Agreement (see note 1) the company has issued new warrants: 7.63 million SPAC Private warrants, 10 million SPAC Public Warrants and 1 miliion Pipe warrants (together with the PAS called "Derivatives"). The Company is required to allocate the Warrants transferred between the identifiable assets received and the listing expense in accordance with IFRIC agenda decision from October 2022. The portion of the Warrants in the scope of IAS 32/ IFRS 9 would be recognized as a liability on initial recognition and re-measured through P&L until settlement. The total value of the new SPAC warrants was $ 25 $ $ On December 8, 2022, 3.364 million SPAC private warrants were exercised on a cashless basis ordinary On December 11, 2022, 0.935 million PIPE warrants were exercised 2 million ordinary SPAC Warrants Balance at December 31, 2022 407 Issuance of warrant (SPAC transactions) - Changes in fair value recognized in finance expenses (407 ) Exercise of warrants - Balance at December 31, 2023 - g. Price Adjustment shares: Immediately following the closing of the SPAC transaction, the Company issued a total of 27,500,000 Price Adjustment Shares ("PAS) with the Company’s founders receiving 27,000,000 Price Adjustment Shares (18,000,000 to Yoav Leibovitch and 9,000,000 to Simona Gat) and the Sponsor receiving 500,000 Price Adjustment Shares. In November 2023, we issued to FP, 1,000,000 Price Adjustment Shares as part of and amendment signed between the parties (See Note 12e). The Price Adjustment Shares vest upon three price adjustment achievement dates: (i) one-third of the Price Adjustment Shares will vest if at any time forty-five (45) days after the date of effectiveness of the applicable registration statement ( File File File The share price targets shall be equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalization, reclassifications, combinations, exchanges of shares and other similar changes or transactions to the SatixFy Ordinary Shares occurring on or after the Closing. In the event of a SatixFy change in control transaction within ten (10) years following the closing of the Business Combination, all of the unvested Price Adjustment Shares not earlier vested will vest immediately prior to the closing of such change in control. If the Price Adjustment Shares do not vest according to the achievement dates in the Business Combination Agreement, or if a change of control has not occurred after the Closing and prior to the date that is ten (10) years following the Closing Date, then any unvested Price Adjustment Shares shall automatically be forfeited back to SatixFy for no consideration. The Company allocated the price adjustment shares between the identifiable assets received and the listing expense (see also note 25). Following the logic of the tentative agenda decision, the portion in the scope of IAS 32/ IFRS 9 would be recognized as a liability on initial recognition and re-measured through the Company’s income statement until settlement. The total value of the Price Adjustment Shares was $212,675 (see note 25) and was divided between equity and liability as follow: $191,132 as equity and $21,543 as liability under derivatives. For the purpose of measuring the price of the Price Adjustment Shares PAS Balance on December 31, 2022 19,898 Changes in fair value recognized in finance expenses (19,784 ) Balance on December 31, 2023 114 For the purpose of measuring the fair value of the PAS derivatives on December 31, 2023 and on December 31, 2022, a binomial model was used. The inputs used in determining the fair value are: a risk-free interest rate of 3.88%, an expected exercise period of 9.063 years and 10.161 years December 31, 2023 and on December 31, 2022, respectivly for and an expected volatility of approximately 50% . For the purpose of measuring the fair value of the PAS derivatives on December 31, 2023, a binomial model was used. The inputs used in determining the fair value are: Price per share: 0.3631 a risk-free interest rate of 3.88%, an expected exercise period of 9.8712 years and an expected volatility of approximately 50%.

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES	12 Months Ended
	Dec. 31, 2023
Disclosure Of Other Long Term Liabilities [Abstract]
OTHER LONG-TERM LIABILITIES	NOTE 16 - OTHER LONG-TERM LIABILITIES: a. Breakdown of other long-term liabilities: December 31, 2023 December 31, 2022 Liability for IIA Royalties (See Note 16(b) below) 1,196 1,107 Alta settlement (See note 19) 300 - 1,496 1,107 b. Liability for royalties payable: The Company received the approval of the IIA for its participation in certain development expenses carried out by the Company, within the framework of determined budgets and time periods. In accordance with its commitment, the Company is obliged to pay the IIA royalties of 3-4% of sales, constituting the revenues derived from sales of the Company’s revenues based on the financing by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase until repayments begin. The difference between the consideration received and the liability recognized at inception (present value) was treated as a government grant according to IAS 20 and recognized as a reimbursement of research expenses or a reduction in capitalized development costs. December 31, 2023 December 31, 2022 At January 1 1,107 1,368 Principal Payments (11 ) (429 ) Amounts recognized as an offset from research and development expenses (113 ) (210 ) Revaluation of the liability 213 378 As of December 31 1,196 1,107

FORWARD PURCHASE AGREEMENT

FORWARD PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2023
Disclosure Of Forwared Purchase Agreement [Abstract]
FORWARD PURCHASE AGREEMENT	NOTE 17 - FORWARD PURCHASE AGREEMENT: The company entered into the Forward Purchase Transaction with the Seller. Pursuant to the Forward Purchase Agreement, the Seller thereunder purchased, through a broker in the open market shares and will sell the shares under certain conditions. Vellar will pay directly, out of the funds held in Endurance’s trust account, approximately $86.5 million. Accordingly, there was no net increase in cash as a result of the Forward Purchase Agreement at the time of the Closing of the Business Combination occurred on October 27, 2023. Upon the effective date of the applicable registration statement January 23, 2023, the Seller paid to SatixFy approximately $10.0 million (including $8.4 million with respect to the Subject Shares purchased by the Seller prior to the closing of the Business Combination and $1.6 million with respect to the Additional Shares issued to Vellar following the Closing of the Business Combination). The difference between the fair value of the shares deemed to be issued to the SPAC holders, including the Seller's and the net financial instruments held by the SPAC (including the fair value of the FPA) are recognized as listing expenses. The financial instrument was measured at fair value initially and subsequently, with changes in fair value recognized in profit or loss . For the purpose of measuring the price of FPA assets a Monte Carlo simulation model was used. The inputs used in determining the fair value are: risk-free rate of 4.30%, volatility of 50% and contractual time of 3 years. The FPA liability value for October 27, 2022 is On October 31, 2023, the Company entered into a termination agreement with the Seller, dated October 31, 2023. Pursuant to the termination agreements, the parties agreed (i) terminating Forward Purchase Agreement, (ii) that Vellar and ACM relinquish their rights to an aggregate of 3,599,444 ordinary shares (which includes all remaining Subject Shares held by ACM and Vellar), which are to be transferred to FP in connection with their consent to the transactions contemplated by the MDA Agreement (See also Note 12(d). Further, the Company agreed to pay Vellar and ACM an aggregate amount of approximately $6.5 million in installments until May 31, 2024, in the case of Vellar, and March 31, 2024, in the case of ACM. The Termination Agreements further provide that if the Company fails to make the required payments to ACM on time (subject to certain conditions as described therein), the total amount payable by us to ACM will increase by $3.7 million (which amount will be payable on the final installment date). At January 1, 2022 - FPA (SPAC transactions)- Assets 42,502 FPA (SPAC transactions)- Liability (13,306 ) FPA (SPAC transactions) net 29,196 Revaluation as of 21.11.2022 (36,692 ) Issuance of shares in 21.11.2022 49,998 Revaluation as of 31.12.2022 (1,650 ) As of December 31, 2022 40,852 Cash received (10,026 ) Revaluation as of October 2023 (37,408 ) Termination (6,582 ) As of December 31, 2023 -

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
EQUITY	NOTE 18 - EQUITY: a. Ordinary share: Ordinary share confers upon its holders the rights to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends if declared. b. SPAC merger: Prior to the SPAC Transaction (see Note 1), in additional to the ordinary shares, the Company held three classes of preferred shares (A, B and C) which beard different rights and preferences and which were issued at early stages of the Company, All Preferred Shares were converted into Ordinary Shares and the company has canceled its par value of the Ordinary Shares. In addition, all shares were split by exchange ratio of 1.046. c. Share Option Plan: On September 4, 2013, the Company’s board directors adopted for the first time the 2013 Share Incentive Plan pursuant to which the board of directors is authorized to issue share options, restricted share and other awards to officers, directors, employees, consultants and other service providers of the Company’s Israeli subsidiary. Each option can be exercised for one ordinary share with a par value of $0.008 per share. Each option is exercisable over up to 10 years from the grant date. On May 12, 2020 following the Reorganization described in Note 1(a) the board of directors adopted 2020 Share Award Plan replacing the 2013 Share Incentive Plan and all the Israeli employees were re granted according to the 2020 Share Award Plan after receiving an approval from the Israeli Tax Authorities for tax exemption in accordance with the provisions of section 104B (f) of the Income Tax Ordinance. The Options granted under the 2013 Share Incentive Plan and under 2020 Share Award Plan are subject to Section 102 of the Israeli Tax Ordinance, the minimum period in which the Allocated Options granted to a participant or, upon exercise or vesting thereof the Underlying Shares, are to be held by the Trustee on behalf of the participant, in accordance with Section 102, and pursuant to the Tax Track which the Company selects subject to the provisions of Section 102(g) of the Israeli Tax Ordinance. In 2022, the Company granted 1,405,568 options to purchase shared of the Company’s employees. The Company didn’t grant options in 2023. In 2023 and 2022, 229,760 and 225,964 options respectively were exercised by employees and converted to shares. As of December 31, 2023 and 2022, 6,214,912 and 7,297,303 options to purchase the C ompany’s shares were outstanding, respectively, of which 2,669,614 were exercisable as of December 31, 2023. In 2023 the Company granted for the first time 7,808,280 Restricted Stock Units (“RSU”) to employees and subcontractors. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of four years with 1 year cliff and thereafter a quarterly vesting over the remaining of 3 years. The RSUs that were granted to the Israeli employees were granted under Section 102 of the Israeli Tax Ordinance. As of December 31, 2023, 5,219,101 RSU are outstanding. On May 4, 2017 the Company’s board of directors approved EMI share option scheme pursuant to which the board of directors is authorized to issue share options, restricted share and other awards to officers, directors, employees, consultants and other service providers of the Company’s UK subsidiaries. Each option can be exercised for one ordinary stock with a par value of $0.008. Options granted vest in equal tranches over three years from the grant date. Each option is exercisable up to 10 years from the grant date. On May 12, 2020 following the Reorganization described in Note 1(a) the board of directors adopted 2020 EMI Share Option Plan replacing the EMI share option scheme and all the employees in UK were re granted according to the 2020 EMI Share Option Plan. Under the rules of the scheme, share options only become exercisable upon an exit event. An exit event is defined as the sale or transfer of the whole of the undertaking or assets of the company and its subsidiaries or a successful listing on a recognized share exchange. If the share options remain unexercised after a period of ten years from the date of grant the share options will automatically lapse and cease to be exercisable. In the event that an employee leaves the employment of the company or its group, for whatever reason (including death), all share options are forfeited immediately. All share options granted are non-assignable under the rules of the scheme and any ordinary shares ultimately acquired on the exercise of a share option are subject to certain restrictions as stipulated in the company’s articles of association. The following table summarizes information about share options outstanding and exercisable as of December 31, 2023: Options Outstanding Options Exercisable Number Outstanding on December 31, 2023 (in thousands) Weighted Average Number Exercisable on December 31, 2023 (in thousands) Exercise Price Years USD 768 1.06 768 0.0001 563 0.17 563 0.536 260 4.46 260 0.550 1,162 5.26 1,095 1.102 3,462 7.1 485 2.5 6,215 3,171 2023 2022 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price USD USD Options outstanding at the beginning of year: 7,297 1.76 7,710 1.72 Changes during the year: Granted - - 1,405 2.50 Exercised 38 0.68 226 0.42 Forfeited 1,044 2.38 1,592 0.22 Options outstanding at end of year 6,215 1.67 7,297 1.76 Options exercisable at year-end 3,171 0.90 3,169 0.87 The fair value of each option granted is estimated on the date of grant, using the Black-Scholes framework with the following assumptions: dividend yield of 0% for all years; expected volatility:– 40%-60%; risk-free interest rate: 0.1%-2.5%-; and expected life: 2-4 years. The Company is required to assume a dividend yield as an input in the Black-Scholes model. The dividend yield assumption is based on the Company’s historical experience and expectation of future dividends payouts and may be subject to change in the future. The RSUs to employees and services providers outstanding as of December 31, 2023 as follows: Number of RSUs Outstanding at beginning of year - Granted 7,808,280 Vested (902,753 ) Forfeited (1,686,426 ) Unvested as of December 31, 2023 5,219,101

MATERIAL COMMITMENTS

MATERIAL COMMITMENTS	12 Months Ended
	Dec. 31, 2023
Disclosure Of Commitments Abstract
MATERIAL COMMITMENTS	NOTE 19 – MATERIAL COMMITMENTS: a. The Company’s UK subsidiaries had signed several agreements with the European Space Agency (hereinafter: “ESA” or “The Agency”) as part of the Agency’s ARTES programs. The objectives of ARTES programs are to ensure the readiness of the industry to respond to commercial opportunities by focusing the activities on technological innovation in equipment, systems, and applications for satellite communication, resulting in products ready for future exploitation within either the commercial or institutional market. Accordingly, the Agency had agreed to participate in the funding of the development of an integrated chip sets for several industries, which includes both hardware and software. The Agency’s participation varies between 50%-75% of the cost, depending on the nature of the engagement. The grants are recognized in the statement of operations as a reduction of research and development expenses and are recognized when the Company is entitled, on the basis of the accumulation of expenses for which the grants are received. The Agency does not require any future royalties nor any ownership of the Intellectual Property (“IP”) resulting from the development which is owned by the Company’s UK subsidiaries, however, the agreement do stipulates that the IP will be available to the Agency on a free, worldwide license for its own requirements, The Agency can require the Company to license the IP to certain bodies that are part of specified Agency programs, for the Agency’s own requirements on acceptable commercial terms and can also require the Company to license the IP to any other third party for purposes other than the Agency’s requirements subject to the approval of the Company that those other purposes do not contradict its commercial interests. Grants received from ESA are recognized in the statement of operations as a reduction of the research and development expenses and are recognized when the Company is entitled, on the basis of the accumulation of expenses for which the grants are received. b. The Israeli Subsidiary also participated in programs that were financed by the Government of Israel for supporting research and development activities. As of December 31, 2022, the Israeli Subsidiary had obtained grants from the IIA to finance its research and development programs in the aggregate of $6,334 thousand, of which $3,289 bear royalties. In return for financing these programs, the Israeli Subsidiary committed to pay the IIA royalties of 3%-4% of total sales of products from revenues related to these programs. The royalties will be paid up to a maximum amount representing 100% of total grants received and are linked to the U.S. dollar exchange rate with the addition of an annual dollar interest rate. As of December 31, 2022, and December 31, 2020 the Israeli Subsidiary has accumulated liability in respect of royalties to the IIA in the amount of $314 and $916 thousand, respectively, representing 3%- 4% of revenues. As of December 31, 2023, and December 31, 2022, the Israeli Subsidiary has a contingent liability to IIA in the amount of $1,107 and $1,368, respectively, based on discounted future royalties at an interest rate of 20%, respectively. Legal proceedings: The Company, SatixFy Limited, and certain shareholders and directors of the Company (the “Defendants”) were served with two lawsuits filed in the district court in Tel Aviv on March 22, 2022, by certain plaintiffs purporting to be stockholders of the Company (the “Plaintiffs”). Based on their prior stakes in Satixfy Limited, a company incorporated in Hong Kong, whose business was assigned to the Company in exchange for the issuance of equivalent holdings in the Company, except for certain shares placed in trust for the benefit of certain service providers, the Plaintiffs claim they are entitled to an aggregate of 2,000,000 Ordinary Shares of the Company and that the said trust mechanism does not pertain to them. The Plaintiffs ask for the amendment of the Company’s shareholders register accordingly, (ii) an order enjoining the defendants from executing any transaction or taking any other action that could adversely and disproportionally affect the Plaintiffs’ rights as shareholders, and (iii) the Defendants to notify the relevant regulatory authorities of the plaintiffs’ claim. The Company issued and placed in trust sufficient shares to provide for the Plaintiffs’ alleged stakes in the Company should the Plaintiffs prevail on the merits. In May 2022, the On October 27, 2022, Sensegain Prodigy Cayman Fund SP3 (“Sensegain”) defaulted on its commitment to purchase units it had subscribed for in connection with the PIPE financing pursuant to its Subscription Agreement with SatixFy and Endurance. As a result of the default, out of the $29,100,000 previously committed by subscribers pursuant to the Subscription Agreements, SatixFy received $20 million in proceeds from the PIPE financing. On December 12, 2022, we filed a complaint against Sensegain in the New York Supreme Court, County of New York, seeking specific performance by Sensegain under the Subscription Agreement or, in the alternative, damages in the amount Sensegain owes pursuant to the Subscription Agreement (plus applicable interest and fees). We intend to withdraw this matter due to enforceability limitations. In June 2023, Alta Partners, LLC (“Alta”) filed a complaint against us in the U.S. District Court for the Southern District of New York claiming unspecified damages for an alleged breach by us of the warrant agreement in relation to certain of its public warrants allegedly held by Alta. In December 2023, the Company and Alta reached a settlement agreement according to which, the Company shall pay to Alta the sum of $2.3 million as follows: (i) $1 million no later than five (5) business days after the Effective Date; and (ii). $1.3 million in thirteen (13) monthly installments of one hundred thousand ($100,000) each with the first instalment no later than March 1, 2024. Upon reception of the first installment Alta had agreed to dismiss all actions in against the Company. Covenants: The FP loan has several Covenants- See note 11. Royalty commitments: The Company receives research and development grants from the IIA. In consideration for the research and development grants received from the IIA, the Company has undertaken to pay royalties as a percentage of revenues from products developed from research and development projects financed. If the Company does not generate sales of products developed with funds provided by the IIA, the Company is not obligated to pay royalties or repay the grants. Royalties are payable at the rate of 3%-4% from the time of commencement of sales of all of the Company’s products until the cumulative amount of the royalties paid equals 100% of the dollar-linked amounts of the grants received, plus interest at LIBOR. Until October 25, 2023, the interest was calculated at a rate based on 12-month London Interbank Offered Rate, or LIBOR applicable to US Dollar deposits. However, on October 25, 2023, the IIA published a directive concerning changes in royalties to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest will be calculated at a rate based on 12-month Secured Overnight Financing Rate, the SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest will be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.

REVENUES

REVENUES	12 Months Ended
	Dec. 31, 2023
REVENUES
REVENUES	NOTE 20 - REVENUES: The Company splits its revenues from contracts with customers in accordance with contracts for provision of R&D services and products as presented in the statement of comprehensive loss. The Company is organized as one operating segment. Main customers: 1. Transactions with main customers: The company has four main customers: MDA, for which revenues were reported as revenues from provision of development services, a confidential customer, for which revenues were reported as revenues from provision of development services, Telesat, for which revenues were reported as revenues from provision of development services and iDirect, for which revenues were reported as revenues from sale of products. For the year ended December 31, 2023 2022 2021 USD thousands % USD thousands % USD thousands % Jet Talk - - - - 3,116 14 % Airbus 188 2 % 318 3 % 3,256 15 % Telesat 4,250 40 % 5,326 50 % 8,400 39 % iDirect 2,605 24 % 489 5 % 2,074 10 % Trustcom - 0 % 1,108 10 % - - MDA 1,497 14 % 1,907 18 % - - Confidential Customer 1,309 12 % 1,162 11 % - - 2. Geographical areas: The following table splits the Company’s revenues by main geographical areas: US & Canada UK Other Consolidated 2023 2022 2021 2023 2022 2021 2023 2022 2021 2023 2022 2021 Revenues 8,446 9,310 13,196 732 1,070 7,325 1,552 246 1,199 10,730 10,626 21,720

COST OF SALES AND SERVICES

COST OF SALES AND SERVICES	12 Months Ended
	Dec. 31, 2023
Cost Of Revenue And Service Abstract
COST OF SALES AND SERVICES	NOTE 21 - COST OF SALES AND SERVICES: December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 2,861 3,556 6,764 Materials and models 2,276 707 1,516 Depriciation 34 21 56 Chip Development tools and Subcontractors 767 214 507 Total 5,938 4,498 8,843

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES, NET	12 Months Ended
	Dec. 31, 2023
Research And Development Expenses [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET	NOTE 22 - RESEARCH AND DEVELOPMENT EXPENSES, NET: For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses, including Stock Based Compensation 23,450 21,923 18,810 Chip pre-production and Development tools 9,917 7,214 12,936 Government support and grants (4,241 ) (12,295 ) (13,802 ) Total 29,126 16,842 17,944

SELLING AND MARKETING EXPENSES

SELLING AND MARKETING EXPENSES	12 Months Ended
	Dec. 31, 2023
Selling And Marketing Expenses [Abstract]
SELLING AND MARKETING EXPENSES	NOTE 23 - SELLING AND MARKETING EXPENSES: For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 2,866 2,335 1,752 Total 2,866 2,335 1,752

ADMINISTRATIVE AND GENERAL EXPE

ADMINISTRATIVE AND GENERAL EXPENSES	12 Months Ended
	Dec. 31, 2023
Administrative And General Expenses [Abstract]
ADMINISTRATIVE AND GENERAL EXPENSES:	NOTE 24 - ADMINISTRATIVE AND GENERAL EXPENSES: For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 5,925 8,175 3,233 Depreciation and overheads 93 132 240 Expected Credit Loss (a) 1,876 - - Other expenses (b) 6,667 942 262 Total 14,561 9,249 3,735 (a) Write off of a contract asset relating to Jet-Talk contract asset balance, as the Company does not believe it can benefit from the remaining asset due to certain disagreement between the parties, which are under discussion and expected to be resolved in the near future. (b) In 2023 expenses occurred following the Alta settlement of $2.3 million (see Note 19) and new D&O Insurance policy expenses.

LISTING EXPENSES

LISTING EXPENSES	12 Months Ended
	Dec. 31, 2023
Disclosure Of Listing Expenses [Abstract]
LISTING EXPENSES:	NOTE 25 - LISTING EXPENSES: Share listing expense is a non-recurring expense incurred in connection with the Business Combination of Satixfy and Endurance , which constituted a share-based transaction pursuant to IFRS 2. The share listing expense is determined as the excess of the fair value of the equity instruments issued by Satixfy over the fair value of the identified net assets contributed by in the Business Combination. Note October 27, 2022 Price Adjustment Shares 212,675 Issuance of shares 149,657 Private Warrants 15 1,681 Public Warrants 15 2,203 PIPE Warrants 15 22 Net Liability of Business Combination 687 Forward Purchase Agreement- Liabilities 17 13,306 380,231 Total Cash (7,813 ) Forward Purchase Agreement- Assets 17 (42,502 ) (50,315 ) Other Listing Expenses 3,410 Total 333,326 The Company’s share listing expenses are a non-recurring nature and only impact the 2022 financial statements as the Company listed on NYSE in 2022. Quantity Price Total Amount Price Adjustment Shares 27,500 7.73 212,575 2 Premium- SPAC shares 14,800 10.11 149,628 3 Warrants 18,630 0.22 4,099 1 Forward Purchase Agreement- Liabilities 1,605 8.29 13,305 1 Forward Purchase Agreement- Assets 42,502 4 (1) Price based on the public price in the closing date. (2) See note 15. (3) Price based on the market price prior to the SPAC transaction. (4) See note 17.

TAX EXPENSES

TAX EXPENSES	12 Months Ended
	Dec. 31, 2023
TAXES ON INCOME
TAXES ON INCOME	NOTE 26 – TAX EXPENSES: A. Tax base: UK: The corporate tax rate in the UK was 19% in the years 2023 and 2022. The tax payable is based on the taxable profit for the year. The taxable profit is different than the net profit as reported in the profit and loss account since it does not include items of income or expense that are taxable or tax deductible carried forward from other years and does not include items that are not taxable or not tax deductible at all. The Group's current tax liability is calculated according to tax rates that have been acted or that their enactment has actually been completed by the end of the reporting period. Israel: The Company's Israeli subsidiaries are subject to the tax laws of the State of Israel, whose overall tax rate was 23% in 2023 and in 2022. The company is entitled to various tax benefits in Israel by virtue of its status as a "preferred enterprise" as defined in the tax regulations. The benefits include, among other things, a reduced tax rate. In December 2010, an amendment was adopted to the Capital Investment Encouragement Law of 1959, or “the Investment Law". This new legislation came into force on 1 January 2011 and applies to preferred income produced or generated by a preferred enterprise from the date of commencement. Under this legislation, a unified corporate tax rate applies to all income that meets the conditions of certain industrial companies, or preferred enterprises (as defined in the Investment Law), in contrary to the previous law incentives, which were limited to income from approved enterprises and licensed enterprises during their benefit period. According to the legislation, the unified tax rates are as follows: 12% or 6% in development areas. B. Uncertain tax position: The Company did not record any liability in respect of income taxes related to deferred tax benefits at the date of adoption and did not record any liability in respect of deferred tax benefits during 2023 and 2022. Accordingly, the Company has not recorded any interest or penalty for any unrecognized benefit. The Company recorded a tax liability following the MDA Agreement (See note 3). C. Tax losses: As of December 31, 2023, the Company has a carry-forward loss of approximately $86 million, according to the 2023 tax return, which may be utilized to offset taxable income in the future. The Company did not create deferred taxes due to the uncertainty in their future utilization. D. Tax assessments: The Company has not yet received final tax assessments in any of its subsidiaries.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
LOSS PER SHARE	NOTE 27 - LOSS PER SHARE: Below are the net loss data attributed to capital rights owners. The loss per share is calculated according to the weighted average number of the shares issued in the relevant financial periods, the weighted average number of the ordinary shares issued and the loss for the period as follows: For the year ended December 31 2023 2022 2021 Calculation of basic earnings per share: Net loss (29,715 ) (397,789 ) (17,050 ) Loss attributed to ordinary shareholders in USD (29,715 ) (397,789 ) (17,050 ) Weighted average number of ordinary shares 80,974,653 30,030,805 18,732,473 Basic and diluted loss per share attributed in USD (0.37 ) (13.25 ) (0.91 )

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Basis of preparation	A. Basis of preparation: These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and Interpretations (collectively “IFRS”) . The financial statements have been prepared under the historical cost convention except for certain financial liabilities which are measured at fair value untit conversion. The Company has elected to present the consolidated statements of comprehensive loss using the function of expense method.
Basis of consolidation	B. Basis of consolidation: Subsidiaries: Where the Company has control over an investee, it is classified as a subsidiary. The Company controls an investee if all three of the following elements are present: power over the investee, exposure to variable returns from the investee, and the ability of the investor to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control. The consolidated financial statements present the results of the Company and its subsidiaries as if they formed a single entity. Intercompany transactions and balances between Group companies are therefore eliminated in full. In addition, the financial statements of the subsidiaries were prepared using a consistent accounting policy with the Company regarding similar transactions and events in similar circumstances. Investments in affiliated companies and joint ventures: When the Company has the ability to influence the business operation of another entity, but the influence does not constitute control, then the Company has a significant influence which will be presented as an affiliate company and accounted for based on the equity method. Potential voting rights which can be exercised on an immediate basis also taking into account as part of the above influence. The holding in an affiliate company is presented based on the equity method unless the investment is held for sale. The financial statements of the affiliated company have been prepared using the same accounting policy of the Company. Any goodwill arising from the affiliated company purchase is part of the investment and is not amortized unless there is objective evidence for impairment. If the Company's share in the losses of an affiliated company or joint venture is equal to or exceeds its rights in the affiliated company or in the joint venture, the Company ceases to recognize its share in additional losses. Once the Company's rights have been reduced to zero, the Company recognizes additional losses only to the extent that it has incurred legal or implied liabilities or to the extent that payments have been made for the affiliated company or for the joint venture. The Company recognizes the gains that arise thereafter only when the Company's share in the profits equals the share in unrecognized losses. The Company performs an impairment test (see Note 2.T below) for a net investment in an affiliated company or in a joint venture as a whole when there is objective evidence of impairment of the investment. An impairment loss is allocated to an investment as a whole. The Company ceases to use the equity method as of the date on which an investment ceases to be an affiliated company or joint venture. Any investment remaining in the former affiliate or former joint venture is measured at fair value. The difference between the fair value of the remaining investment and any consideration from the realization of part of the investment and the book value of the investment at the time the use of the equity method is discontinued is recognized in profit or loss. Amounts previously recognized in other comprehensive income with respect to the same investment are treated in the same manner that would have been required if the invested entity had itself realized the related assets or related liabilities. Transactions eliminated on consolidation: Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. Unrealized gains arising from transactions with associates and joint ventures are eliminated to the extent of the Group’s interest in these investments. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.
Use of critical estimates and assumptions in the preparation of the financial statements	C. Use of critical estimates and assumptions in the preparation of the financial statements: The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. By their nature, these estimates are subject to measurement uncertainty and are reviewed periodically and adjustments, if necessary, are made in the year which they are identified. Actual results could differ from those estimates. The following is a description of assumptions about the future and other factors for uncertainty in estimates at the end of the reporting period, which results in a significant risk that will result in material correlation to book values ​​of assets and liabilities during the next reporting period: Useful life of fixed assets and intangible assets – Useful life is based on management’s estimates of the period in which the assets will generate income, which are reviewed periodically for the purpose of examining the adequacy of these estimates. Changes in management’s estimates may lead to material changes in depreciation expense recognized in profit or loss. Fair value of financial instruments – The fair value of financial instruments that are not quoted in an active market is measured in accordance with model-based valuation techniques. These techniques are significantly influenced by assumptions that serve as a basis for calculation, such as capitalization rates and estimates of future cash flows. Inventory - The net realizable value of the inventory is reviewed at the end of each reporting period. Factors that may affect selling prices include the existing market demand for the company's inventory, the activity of competitors in the market, superior technology in the market, the prices of raw materials and the bankruptcy of customers and suppliers. Estimates of Receipts or Payments of Financial Instruments - If the Company updates the estimates of receipts or payments of financial instruments, it adjusts the value in the books of the financial instrument to reflect the actual cash flows and the updated estimate of the cash flows. Contracts with customers - Measuring the progress of performance commitments that exist over time the company estimates the total cost of completing each project based on estimates of material costs, labor costs, subcontractor performance and more.
Foreign currency	D. Foreign currency: The consolidated financial statements are prepared in U.S. Dollars (which is the functional and reporting currency of the Company). Transactions and balances in foreign currencies are converted into US Dollars in accordance with the principles set forth by International Accounting Standard (IAS) 21 "The Effects of Changes in Foreign Exchange Rates". Accordingly, transactions and balances have been converted as follows: • Monetary assets and liabilities – at the rate of exchange applicable at the consolidated statements of financial position date. • Exchange gains and losses from the aforementioned conversion are recognized in the statement of comprehensive loss. • Expense items – at exchange rates applicable as of the date of recognition of those items. • Non-monetary items are converted at the rate of exchange used to convert the related consolidated statements of financial position items (i.e., at the time of the transaction). Foreign operations: On consolidation, the results of foreign operations are translated into US Dollars at exchange rates ruling when the transactions took place. All assets and liabilities of foreign operations, including goodwill arising on the acquisition of those operations, are translated at the rate ruling at the reporting date. Exchange rate differences arising on translating the opening net assets at opening rate and the results of foreign operations at actual rate of exchange are recognized in other comprehensive income and accumulated in the foreign exchange reserve. Exchange differences recognized in profit or loss in the Group entities' separate financial statements on the translation of long-term monetary items forming part of the Group's net investment in the foreign operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange reserve on consolidation. On disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to that operation up to the date of disposal are classified to profit or loss as part of the profit or loss on disposal.
Cash and cash equivalents	E. Cash and cash equivalents: Cash equivalents are considered by the Company to be highly liquid investments, including, inter alia, short-term deposits with banks where the maturity of which does not exceed three months at the time of deposit and which are not restricted. Overdrafts, which are due on demand and form an integral part of the Company's cash management, were included as a component of cash and cash equivalents for the purposes of presenting the statement of cash flows.
Linkage	F. Linkage: Assets and liabilities linked to the consumer price index were included according to the appropriate index for each asset or liability. CPI-linked loans are measured at reduced cost when the balance at the end of the reporting period is CPI-linked.
Provisions	G. Provisions: Provisions are recognized when the Company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result, and that outflow can be reliably measured. Provisions are measured using the best estimate of the amounts required to settle the obligation at the end of the reporting period. The effect of the time value is material, the amount of the provision is measured according to the present value of the projected expenses that will be required to settle the obligation. The reduction of a provision is recognized in profit or loss as the reduction of the appropriate consequential item when the Company actually bears it or at the date of its termination, whichever is later.
Research and development costs	H. Research and development costs: Expenditure on research activities is recognized in profit or loss as incurred. Expenditure incurred on development activities including the Company’s development is capitalized where the expenditure will lead to new or substantially improved products and only if all the following can be demonstrated: • the product is technically and commercially feasible; • the Company intends to complete the product so that it will be available for use or sale; • the Company has the ability to use the product or sell it; • the Company has the technical, financial and other resources to complete the development and to use or sell the product; • the Company can demonstrate the probability that the product will generate future economic benefits; and. • the Company is able to measure the expenditure attributable to the product during the development. Recognition of costs in the carrying amount of an intangible asset, ceases, when the asset is in the condition necessary for it to be capable of operating in the manner intended by management. Capitalized development costs are amortized on a straight-line basis over their estimated useful lives once the development is completed and the assets are in use. Subsequent expenditure on capitalized intangible assets is capitalized only where such expenditure clearly increases the economic benefits to be derived from the asset to which it relates. All other expenditure, including that incurred in order to maintain an intangible assets current level of performance, is expensed as incurred. The Company did not meet the requirements for capitalization of research and development expenses during the periods covered by this report.
Leases	I. Leases: The Company applied the following practical expedients when applying IFRS 16 to leases previously classified as operating leases: • Applied a single discount rate to a portfolio of leases with reasonably similar characteristics. • Applied the exemption not to recognize right-of-use assets and liabilities for leases with less than 12 months of lease term remaining as of the date of initial application and do not contain a purchase option. • Applied the practical expedient provided by the standard to recognize right-of-use assets equal to the lease liability upon initial application. Under IFRS 16, the Company recognizes right-of-use assets and lease liabilities for most leases. The Company adopted IFRS 16 using the modified retrospective approach, with recognition of transitional adjustments on the date of initial application (January 1, 2019), without restatement of comparative figures. On initial application of IFRS 16, the Company recognized right-of-use assets and lease liabilities in relation to leases of office facilities and motor vehicles, which had previously been classified as operating leases. The lease liabilities were measured at the present value of the remaining lease payments, discounted using the Company’s incremental borrowing rate as at January 1, 2019. The Company’s incremental borrowing rate is the rate at which a similar borrowing could be obtained from an independent creditor under comparable terms and conditions. The weighted-average rate applied was 4.5%. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments. Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any accumulated impairment losses, and adjusted for any re-measurement of lease liabilities. The cost of right-of-use assets comprises the amount of the initial measurement of the lease liability; lease payments made at or before the commencement date less any lease incentives received; and initial direct costs incurred. The recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option that is reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. Lease term: The term of a lease is determined as the non-cancellable period for which a lessee has the right to use an underlying asset, together with both periods covered by an option to extend the lease if the lessee is reasonably certain to exercise that option periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option.
Share-based payment	J. Share-based payment: The Company has recognized share-based payment transactions, inter alia, for the purchase of goods or services. These transactions include transactions with employees and non-employee parties that will be settled in the Company's equity instruments, such as shares or stock options, or that will be settled in cash based on the price or value of the Company's equity instruments, and transactions that allow the Company to choose between cash in cash and disposal in the company's equity instruments. In the case of share-based payment transactions for employees disposed of in equity instruments, the value of the benefit is measured at the time of grant with respect to the fair value of the equity instruments granted. With respect to share-based payment transactions for non-employee parties settled in equity instruments, the value of the transaction is measured with respect to the fair value of the goods and/ or services received. If the Company is unable to reliably measure the fair value of the goods or services received, their fair value is measured with respect to the fair value of the equity instruments granted. In the case of share-based payment transactions that are settled in cash, the value of the benefit is presented as a liability, which is measured at fair value at the end of each reporting period and at the date of settlement. The benefit value of share-based payment transactions is recognized in profit or loss, unless the expense is included in the cost of an asset, against a capital fund over the vesting period based on the best estimate obtainable of the number of equity instruments expected to mature. When the Company received services in exchange for a payment granted based on the Company's equity instruments, it is a share-based payment transaction that is settled on equity instruments, so that an expense is recognized in profit or loss. When changes are made to a share-based payment plan, the Company recognizes the effects of changes that increase the total fair value of the plan during the remaining vesting period.
Transactions with related parties	K. Transactions with related parties: An asset transferred to the Company by its related parties is presented in the Company's financial statements at its fair value at the date of the transfer. Any difference between the amount of consideration determined for the property and its fair value was recognized in equity. An asset transferred from the Company to its related parties is deducted from the Company's financial statements at its fair value at the date of the transfer. The difference between the fair value of the property and the book value at the date of transfer is recognized in profit or loss and the difference between the amount of consideration determined for the property at the time of transfer and its fair value is recognized in equity. When the Company's liability to a third party, in whole or in part, is taken by a related party, the liability is deducted from the Company's financial statements at fair value at the date of settlement when the difference between the book value of the liability and the fair value at the date of disposal is recognized in profit or loss. The obligation at the time of settlement and the amount of consideration is determined by a capital seller.
Loss per share	L. Loss per share: Loss per share is calculated by dividing the net loss attributed to the Company's shareholders by the number of weighted ordinary shares that exist during the period. The basic loss per share includes only shares that actually exist during the period. Potential ordinary shares (convertible securities such as convertible bonds, warrants and employee stock options) are included only in the calculation of diluted earnings per share to the extent that their effect dilutes loss per share by converting them to decreases earnings per share or increases losses per share. In addition, potential ordinary shares converted during the period are included in the diluted earnings per share only up to the date of conversion, and from that date are included in the basic loss per share.
IIA grants	M. IIA grants: A grant from the “Israel Innovation Authority” (or “IIA”) received for research and development activities, for which the Company undertook making royalties’ payments to the government contingent on making future sales resulting from such grant financing, was treated as a loan that could be forgiven and recognized as a reimbursement of related research expenses or development costs. The grant was recognized as a liability in the financial statements. Unless there is reasonable assurance that the Company will meet the conditions for the forgiveness of the loan, then it has been recognized as a government grant. When the liability to the government does not bear market interest, the liability was recognized at its fair value in accordance with the market interest rate at the time the grant was received. The difference between the consideration received and the liability recognized in the statement of financial position at the time of receiving the grant was treated as a government grant and recognized as a reimbursement of research expenses or as a reduction of development costs capitalized as the case maybe. Repayment of the liability to the government is reviewed every reporting period, with changes in the liability resulting from a change in the expected royalties recognized in profit or loss.
Credit costs	N. Credit costs: The Company recognized credit costs as an expense in the period of formation, except in cases where they can be directly attributed to the acquisition, construction or production of eligible assets, and in such cases these costs were capitalized as part of the cost of those assets. The Company capitalized credit costs when exits were formed in respect of the property, credit costs were formed, and the activities required to prepare the property for its intended use or sale were carried out. The Company stops capitalizing credit costs when substantially all the activities required to prepare the eligible asset for its intended use or sale have been completed. During prolonged periods in which the active development of a qualifying asset has stopped, the Company delayed the capitalization of credit costs.
Capital instrument	O. Capital instrument: Any contract that classifies a residual right in a company's assets after deducting all its liabilities is classified as an equity instrument. Costs directly related to the issuance of an equity instrument are presented in equity less the issue. Rights, options, or warrants offered in proportion to all existing owners of the same type of shares for the purchase of a fixed number of shares for a fixed amount in any currency have been classified as an equity instrument.
Warrants	P. Warrants: Equity Warrants: Receipts in respect of warrants for the purchase of shares of the company/ subsidiary, which give the holder the right to purchase a fixed number of equity instrument (e.g., ordinary shares) in exchange for a fixed amount of cash, are classified as equity. Financial liability: Receipts in respect of warrants for the purchase of shares of the Company, which give the holder the right to purchase a fixed number of ordinary shares in exchange for a variable amount, including when the exercise of the warrants is linked to any index or foreign currency, are classified as liabilities (See also Note 15).
Fair value measurement	Q. Fair value measurement: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: 1. In the principal market for the asset or liability, or 2. In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible to the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. The Company measures the following balances according to Fair value: financial lability warrants. Classification of fair value hierarchy The financial instruments presented in the statement of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value. The classification of an item into the below levels is based on the lowest level of the inputs used that has a significant effect on the fair value measurement of the item. Transfers of items between levels are recognized in the period they occur: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly. Level 3 - Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
Financial instruments	R. Financial instruments: Financial assets: The Company classifies its financial assets into the following categories, based on the business model for managing the financial asset and its contractual cash flow characteristics. The Company's accounting policy for the relevant category is as follows: Amortized cost: These assets arise principally from the services rendered to customers (e.g. trade receivables), but also incorporate other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value plus transaction costs that are directly attributable to their acquisition or issue and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment. Impairment provisions for trade receivables are recognized based. On the simplified approach within IFRS 9 using a provision matrix in the determination of the lifetime expected credit losses. During this process the probability of the non-payment of the trade receivables is assessed. This probability is then multiplied by the amount of the expected loss arising from default to determine the lifetime expected credit loss for the trade receivables. For trade receivables, which are reported net, such provisions are recorded in a separate provision account with the loss being recognized within general and administrative expenses in the consolidated statements of comprehensive income. On assessment that the trade receivable will not be collectable, the gross carrying value of the asset is written off against the associated provision. For this purpose, the Company relied on historical data that includes debt settlement, failure rate of lost debt to each company in the group in the period of the last 5 years up to the date of measurement. The Company updates the impairment provision at the end of each reporting period, and the change in the provision as it exists is recognized as a gain or loss from an impairment loss or loss. At the end of each reporting period the Company assesses whether an asset has been impaired due to credit risk (i.e. if an event has occurred that has a detrimental effect on the future cash flows of the estimated asset). Evidence that a property is defective includes for example a significant financial difficulty of the debtor. The Company writes off the value in the gross books of a financial asset, in whole or in part, when the Company has no reasonable expectation of the return of the asset, for example when the debtor enters into a foreclosure or bankruptcy proceeding. Fair value: All other financial assets, including debt instruments when first recognized at fair value through profit or loss to eliminate or significantly reduce inconsistency in measurement or recognition, were first measured at fair value, and changes in fair value after initial recognition were recognized in profit or loss. Transaction costs that were directly attributed to these assets were recognized in profit or loss at the time they were incurred. Reclassification of measurement groups after initial recognition is not possible unless the Company changes its business model for managing financial assets. Financial liabilities: The Company's accounting policy for its financial liabilities is as follows: • Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive loss. • Amortized cost: other financial liabilities, including bank borrowings, loans from bank, trade payables, loan from major shareholder, leases and financial liability from government grants, are initially recognized at fair value less any transaction costs directly attributable to the issue of the instrument. Such interest-bearing liabilities are subsequently measured at amortized cost using the effective interest method, which ensures that any interest expense over the period is at a constant interest rate on the balance of the liability carried in the statement of financial position. Interest expense in this context includes initial transaction costs, as well as any interest or coupon payable while the liability is outstanding. De-recognition: ● Fair value: This category comprises convertible securities and warrants which are carried in the consolidated statement of financial position at fair value with changes in fair value recognized in the consolidated statement of comprehensive income. ● Financial Liabilities - the Company derecognizes financial liability when its contractual obligations are discharged or cancelled or expire. Impairment of financial assets: The Company assesses at the end of each reporting period whether there is any objective evidence of impairment of a financial asset as follows. Financial assets carried at amortized cost: there is objective evidence of impairment of other accounts receivable if one or more events have occurred after the initial recognition of the asset and that loss event has an impact on the estimated future cash flows. Evidence of impairment may include indications that the debtor is experiencing financial difficulties, including liquidity difficulty and default in interest or principal payments. Write-off policy: The Company writes off its financial assets if any of the following occur: 1. Inability to locate the debtor. 2. Discharge of the debt in a bankruptcy. 3. It is determined that the efforts to collect the debt are no longer cost effective given the size of receivable.
Issue of a unit of financial instruments	S. Issue of a unit of financial instruments: The issue of a unit of financial instruments like a financial liability (e.g., a loan) and free-standing derivative (e.g. warrants) involves the allocation of the proceeds received (before issue expenses) to the instruments issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
Impairment of non-financial assets	T. Impairment of non-financial assets: Other intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit. A cash-generating unit is the smallest group of assets that independently generates cash flow and whose cash flow is largely independent of the cash flows generated by other assets.
Assets and liabilities arising from engagements with customers	U. Assets and liabilities arising from engagements with customers: • Customers - The Company presents an unconditional right to receive consideration as debtors in respect of contracts (customers). The right to compensation is not conditional if only a lapse of time is required until the due date, even if it may be subject to repayment in the future. Upon first recognition of customers, any difference between the measurement of customers in accordance with IFRS 9 and the corresponding amount of recognized revenue will be presented as an expense. The Company treats debtors in respect of contracts as financial assets. • Assets in respect of contracts – The Company presents a right to receive consideration for goods or services transferred to the customer as an asset in respect of a contract, when this right is conditional on a factor other than the passage of time. The Company handles the impairment of an asset in respect of a contract on the same basis as a financial asset at a reduced cost. • Liabilities in respect of contracts – The Company presents an obligation to transfer goods or services to the customer, for which the company has received consideration from the customer (or unconditional consideration that has matured), as an obligation in respect of a contract (advances from customers).
Inventories	V. Inventories: Inventories are recognized at the lower of cost and net realizable value. Cost comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. The Company measures cost of raw materials on a First In First Out ("FIFO") basis and finished goods according to costs based on direct costs of materials and labor.
Property, plant and equipment	W. Property, plant and equipment: Items of property, plant and equipment are initially recognized at cost. Cost includes directly attributable costs and the estimated present value of any future costs of dismantling and removing items. Depreciation is computed by the straight-line method, based on the estimated useful lives of the assets, as follows: % Leasehold Improvement 25-33 (*) Machinery and Equipment 7-14 Computers 33.3 Furniture 15 (*) In case that the duration of the lease contract is less than the lease improvement, the depreciation is being made over the contract’s period. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. The assets’ residual values, depreciation rates, and depreciation methods are reviewed, and adjusted if appropriate, at the end of reporting period year. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is higher than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the profit or loss.
Employee benefits	X. Employee benefits: The Group has several employee benefit plans: 1. Short-term employee benefits: Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits: The plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. In Israel, the Group funds its employee’s contribution plans pursuant to Section 14 to the Severance Pay Law since 2004 under which the Group pays fixed contributions and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods. There are no post-employment benefits in the UK.
Revenue recognition	Y. Revenue recognition: Revenue is recognized based on the five-step model outlined in IFRS 15, Revenue from Contracts with Customers. IFRS 15 sets out a single revenue recognition model, according to which the entity shall recognize revenue in accordance with the said core principle by implementing a five-step model framework: 1. Identify the contracts with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when the entity satisfies a performance obligation . The Company's revenue consists mostly of revenue from the sale of chip development services and the sale of modems for satellite communications and related products. The Company recognizes revenue from chip rendered The Company recognizes revenue from the sale of satellite communications modems and related products when control is transferred to its customers (i.e., once the products have been physically delivered at the agreed location, the Company no longer has a physical holding, and usually has a present right to receive payment and does not retain any significant risks from the products). In most of the Company's product sales, control is transferred when the products are shipped. The Company presents revenues from products and revenues from development and pre-production services in separate line items on its consolidated statement of comprehensive loss. The Company evaluates the products and services committed in each contract in order to determine whether the contract includes a commitment/ or The Company determines the transaction price for each contract based on the consideration that the Company expects to be entitled to for the products or services provided subject to the contract. Sales tax, value added tax and other taxes which are levied by the Company When the Company receives an upfront payment for a multi-period supply agreement (see Master Purchase Agreement on Note 3), the Company adjusts the transaction price in the contract for the time value of money in order to reflect the financing provided by customer. Ancillary items that are not material to the contract are recognized as an expense. When a contract includes a license to use the Company's intellectual property, together with other goods or services, the Company assesses the nature of the combined performance obligation to determine whether it is met over time or at a point in time. When the commitment to the customer is to provide a right of access to the Company's intellectual property, the Company recognizes revenue over time. The Company measures progress towards the fulfillment of the Company's performance obligations in methods based on outputs such as a performance survey completed as of any given date. The Company presents a contract liability (deferred income) when cash payments are received or are due for payment before the Company's performance subject to the contract, including amounts that are repayable. A right to consideration is presented as and asset only when it is not conditional (i.e., when only a lapse of time is required before the due date of the consideration arrives). When the Company delivers goods or services before the customer pays any consideration or before payment’s due date, the Company records it as a contractual asset, which is presented as part of other receivables.
Reverse Merger	AA. Reverse Merger: SatixFy determined that it was the accounting acquirer based on evaluation of the following facts and circumstances: • SatixFy’s existing shareholders have the greatest voting interest in the combined entity. • SatixFy’s directors represent the majority of the board of directors of the combined company following the consummation of the Business Combination. • SatixFy’s senior management were the senior management of the combined company following the consummation of the Business Combination. • SatixFy is the larger entity based on historical operating activity and its employee base. The Business Combination, which is not within the scope of IFRS 3 since Endurance does not meet the definition of a business in accordance with IFRS 3, was accounted for within the scope of IFRS 2. Any excess of fair value of SatixFy Ordinary Shares issued over the fair value of Endurance’s identifiable net assets acquired represented compensation for the service of a stock exchange listing for its shares and was expensed as incurred. According to the International Financial Reporting Interpretations Committee’s (“IFRIC”) final agenda decision from October 2022, an accounting policy that results in allocating all the warrants issued to the acquisition of the stock exchange listing service solely to avoid the warrants being classified as financial liabilities applying IAS 32 would not give rise to a relevant and reliable accounting policy, it was suggested that an entity could allocate the shares and warrants to the acquisition of cash and other financial assets and the stock exchange listing service on the basis of the relative fair values of the instruments issued. Under this allocation method: • Warrants and Price Adjustments Shares ("PAS") in the scope of IFRS 2 will be classified as equity, as they are considered equity-settled share-based payment. • Warrants and price adjustment shares in the scope of IAS 32 will be classified as financial liabilities, as they fail the fixed-for-fixed requirement.
Changes in accounting policies	AB. Changes in accounting policies: New standards, interpretations and amendments adopted from January 1, 2023 The following amendments are effective for the period beginning January 1, 2023: Disclosure of Accounting Policies (Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements); In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2. The amendments aim to make accounting policy disclosures more informative by replacing the requirement to disclose ‘significant accounting policies’ with ‘material accounting policy information’. The amendments also provide guidance under what circumstance, the accounting policy information is likely to be considered material and therefore requiring disclosure. These amendments have no effect on the measurement or presentation of any items in the consolidated financial statements of the Company but affect the disclosure of accounting policies of the Company. The amendments to IAS 8, which added the definition of accounting estimates, clarify that the effects of a change in an input or measurement technique are changes in accounting estimates, unless resulting from the correction of prior period errors. These amendments clarify how entities make the distinction between changes in accounting estimates, changes in accounting policy and prior period errors. These amendments had no effect on the consolidated financial statements of the Company. New standards, interpretations and amendments not yet effective: The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. There are a number of standards, amendments to standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the Group has decided not to adopt early. The following amendments are effective for the period beginning January 1, 2024: • IFRS 16 Leases (Amendment – Liability in a Sale and Leaseback) • IAS 1 Presentation of Financial Statements (Amendment – Classification of Liabilities as Current or Non-current) • Non-current Liabilities with Covenants (Amendments to IAS 1 Presentation of Financial Statements); and • Supplier Finance Arrangements (Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures). The following amendments are effective for the period beginning January 1, 2025: • Lack of Exchangeability (Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates). The Company is currently assessing the impact of these new accounting standards and amendments. The Company does not expect any other standards issued by the IASB, but not yet effective, to have a material impact on the Company. The areas requiring the use of estimates and critical judgments that may potentially have a significant impact on the Group’s earnings and financial position are: capitalization and amortization of development costs and the useful life of property and equipment and share based payment

GENERAL (Tables)

GENERAL (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of General Information About Financial Statements Abstract
Schedule of subsidiaries	Name Holding percentage Held By Country of incorporation 2023 2022 Satixfy Israel LTD. 100 % 100 % Satixfy Communications LTD. Israel Satixfy UK 100 % 100 % Satixfy Communications LTD. England and Wales Satixfy Space Systems UK (See Note 3) 0 % 100 % Satixfy Communications LTD. England and Wales Satixfy Bulgaria 100 % 100 % Satixfy UK Bulgaria Satixfy US LLC 100 % 100 % Satixfy Communications LTD. USA Endurance Acquisition Corporation 100 % 100 % Satixfy Communications LTD. Cayman Islands Name Holding percentage as of December 31, Held By Country of incorporation 2023 2022 Jet talk Limited (“Jet-Talk”) 51 % 51 % Satixfy UK UK

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Schedule of useful life of property, plant and equipment	% Leasehold Improvement 25-33 (*) Machinery and Equipment 7-14 Computers 33.3 Furniture 15

CONTRACT ASSETS (Tables)

CONTRACT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2023
Contract assets [abstract]
Schedule of contract assets	December 31, 2023 December 31, 2022 Related parties (See Note 14) - $ 1,679 Other trade receivables 4,091 3,356 $ 4,091 $ 5,035 December 31, 2023 December 31, 2022 Balance at the beginning of the year 5,035 6,015 Revenue recognition in the period, net 643 (426 ) Provision (1,876 ) - Currency translation adjustments 289 (554 ) Balance at the End of the year $ 4,091 $ 5,035

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2023
Classes of current inventories [abstract]
Schedule of inventories	December 31, 2023 December 31, 2022 Raw materials $ 1,397 $ 817 Finished goods inventory 78 14 $ 1,475 $ 831

LEASE LIABILITIES AND RIGHT O_2

LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET (Tables)	12 Months Ended
	Dec. 31, 2023
LEASE LIABILITIES AND RIGHT OF USE ASSETS
Schedule of carried values of the lease assets recognized and transactions	Buildings Cars Total Cost January 1, 2023 4,918 155 5,073 Additions 662 103 765 Disposals- Sale of SSS (1,741 ) (74 ) (1,815 ) December 31, 2023 3,839 184 4,023 Accumulated Depreciation January 1, 2023 (2,256 ) (23 ) (2,279 ) Additions (916 ) (83 ) (999 ) Disposals- Sale of SSS 1,454 36 1,490 December 31, 2023 (1,718 ) (70 ) (1,788 ) Net Book value December 31, 2023 2,121 114 2,235 Buildings Cars Total Cost January 1, 2022 5,294 82 5,376 Additions 434 156 590 Disposals (810 ) (83 ) (893 ) December 31, 2022 4,918 155 5,073 Accumulated Depreciation January 1, 2022 (2,155 ) (74 ) (2,229 ) Additions (911 ) (32 ) (943 ) Disposals 810 83 893 December 31, 2022 (2,256 ) (23 ) (2,279 ) Net Book value December 31, 2022 2,662 132 2,794 For the year ended December 31, 2023 December 31, 2022 Interest expenses in respect of lease liabilities 337 393 Lease principal payments during the year 927 1,029

INVESTMENT IN JET-TALK (Tables)

INVESTMENT IN JET-TALK (Tables)	12 Months Ended
	Dec. 31, 2023
INVESTMENT IN JET TALK:
Schedule of investments in jet talk	December 31, 2023 December 31, 2022 December 31, 2021 Net loss Company share 442 705 3,722 Company's share in the loss of a company accounted by equity method, net 226 360 1,898

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2023
PROPERTY, PLANT AND EQUIPMENT, NET
Schedule of useful life of property, plant and equipment	Computers Leasehold improvements Furniture Machinery and Equipment Total Cost January 1, 2023 1,092 600 347 1,043 3,082 Additions 113 52 5 65 235 Disposal -SSS sale (13 ) (119 ) - (53 ) (185 ) December 31, 2023 1,192 533 352 1,055 3,132 Accumulated Depreciation January 1, 2023 (832 ) (262 ) (162 ) (183 ) (1,439 ) Additions (156 ) (62 ) (29 ) (61 ) (308 ) Disposal -SSS sale 1 34 - - 35 December 31, 2023 (987 ) (290 ) (191 ) (244 ) (1,712 ) Net Book value December 31,2023 205 243 161 811 1,420 Computers Leasehold improvements Furniture Machinery and Equipment Total Cost January 1, 2022 956 477 345 414 2,192 Additions 136 123 2 629 890 December 31, 2022 1,092 600 347 1,043 3,082 Accumulated Depreciation January 1, 2022 (714 ) (212 ) (138 ) (156 ) (1,220 ) Additions (118 ) (50 ) (24 ) (27 ) (219 ) December 31, 2022 (832 ) (262 ) (162 ) (183 ) (1,439 ) Net Book value December 31,2022 260 338 185 860 1,643

CONTRACT LIABILITIES (Tables)

CONTRACT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Contract liabilities [abstract]
Schedule of contract liabilities	December 31, 2023 December 31, 2022 Balance at the beginning of the year 622 475 Expenses recognition in the period, net 819 540 Currency translation adjustments 279 (393 ) Balance at the end of the year $ 1,720 $ 622

OTHER ACCOUNTS PAYABLE AND AC_2

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2023
Other Accounts Payable And Accrued Expenses [Abstract]
Schedule of other accounts payable and accrued expenses	December 31, 2023 December 31, 2022 Liabilities in respect of employees, wages and institutions in respect of wages 2,584 3,023 Accrued expenses 6,849 4,607 Liabilities to government institutions due to grants received 136 161 Tax accrual 122 - Government departments and agencies 13 52 9,704 7,843

LONG TERM LOANS FROM FINANCIA_2

LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET (Tables)	12 Months Ended
	Dec. 31, 2023
LOAN FROM SHAREHOLDER
Schedule of Long term loans from financial institutions	For the year ended December 31 2023 2022 Long term loans from financial institutions 59,792 54,926

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2023
RELATED PARTIES:
Schedule of transactions with related parties	For the year ended December 31 2023 2022 Revenues from ST Engineering iDirect (“iDirect”) (*) 2,065 489 (*) iDirect is a shareholder of the Company and after SPAC transaction iDirect is no longer a related party due to their decreased holding.
Schedule of key management compensation	For the year ended December 31, 2023: Name Position Scope of Position Holding Rate Salary, bonuses and related expenses Expected Bonus Share- Based Payments Nir Barkan Acting CEO Full Time 0.25% 303 160 129 Ilan Gat (Simona Gat) Former president and COO Full Time 19.47% 605 - 39 Raysat (Yoav Leibovitch) Chairman Full Time 26.35% 1,750 450 39 For the year ended December 31, 2022: Name Position Scope of Position Holding Rate Salary, bonuses and related expenses Expected Bonus Share- Based Payments Ilan Gat (Simona Gat) President and COO Full Time 19.8% 660 40 39 Raysat (Yoav Leibovitch) Chairman Full Time 27.04% 5,065 60 39
Schedule of outstanding balances with related parties	For the year ended December 31 2023 2022 Assets Contract assets (Jet Talk) - 1,679 Jet Talk 75 157 Total Assets 75 1,836 Labilities Raysat Israel LTD. 550 160 Ilan Gat Engineers LTD - 95 Former CEO - 100 Current CEO 190 - Jet Talk - 53 Total Liabilities 740 408

FINANCIAL INSTRUMENTS - RISK _2

FINANCIAL INSTRUMENTS - RISK MANAGEMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Fair value of financial liabilities
Schedule of maximum exposure to credit risk	December 31, 2023 December 31, 2022 Cash 13,979 11,934 Trade accounts receivables 2,260 1,295 Other accounts receivable 2,053 2,166 Promissory Notes 20,000 - Other long term receivables 2,000 - FPA - 40,852 Contract assets 4,091 5,035 Total 44,383 61,282
Schedule of currency risk	December 31, 2023 NIS EUR GBP USD Total Assets: Cash and cash equivalents 1,120 1,372 235 11,252 13,979 Trade receivables - 55 - 2,205 2,260 Prepaid expenses and other account receivables 2,036 17 2,053 Promissory Notes - - - 20,000 20,000 Other long-term receivables - - - 2,000 2,000 Contract Assets - - 128 3,963 4,091 1,120 3,463 363 39,437 44,383 Liabilities: Current liabilities: Current maturities long-term loans - - - - - Liabilities in respect of leases-ST (469 ) - (144 ) (26 ) (639 ) Advanced payments from MDA against future orders - - - (28,138 ) (28,138 ) Trade payables (479 ) (368 ) (284 ) (247 ) (1,378 ) Payables and credit balances (896 ) (618 ) (415 ) (5,942 ) (7,871 ) (1,844 ) (986 ) (843 ) (34,535 ) (38,026 ) Non-current liabilities: Liability for IIA Royalties (1,196 ) - - - (1,196 ) Liabilities in respect of leases-LT (1,558 ) - (495 ) (14 ) (2,067 ) Long term loans from banks - - - (59,792 ) (59,792 ) Net balances (3,478 ) 2,477 (975 ) (54,722 ) (56,698 ) b. Sensitivity analysis: December 31, 2022 NIS EUR GBP USD Total Assets: Cash and cash equivalents 1,281 640 607 9,406 11,934 Trade receivables - 187 804 304 1,295 Prepaid expenses and other - 2,149 - 17 2,166 Derivatives FPA - - - 40,852 40,852 Contract Assets - - 3,720 1,315 5,035 1,281 2,976 5,131 51,894 61,282 Liabilities: Current liabilities: Current maturities long-term loans - - - - - Liabilities in respect of leases-ST (430 ) - (591 ) - (1,021 ) Trade payables (614 ) (324 ) (433 ) (88 ) (1,459 ) Payables and credit balances (2,644 ) (942 ) (721 ) (3,322 ) (7,629 ) (3,688 ) (1,266 ) (1,745 ) (3,410 ) (10,109 ) Non-current liabilities: Liability for IIA Royalties (1,107 ) - - - (1,107 ) Liabilities in respect of leases-LT (1,830 ) - (450 ) - (2,280 ) Long term loans from banks - - - (54,926 ) (54,926 ) Net balances (5,344 ) 1,710 2,936 (6,442 ) (7,140 )
Schedule of sensitivity analysis	December 31, 2023 December 31, 2022 Linked to NIS (3,478 ) (5,344 ) 10 % 10 % (348 ) (534 ) Linked to EUR 2,477 1,710 10 % 10 % 248 170 Linked to GBP (975 ) 2,936 10 % 10 % (97 ) 294
Schedule of maturity analysis of financial liabilities	December 31, 2023 Within 30 days 1-12 Months 1-5 Years Total Liabilities in respect of leases-ST 172 467 - 639 Trade payables 258 1,120 - 1,378 Promissory Notes - 20,000 - 20,000 Other long term receivables - - 2,000 2,000 Payables to related parties - 740 - 740 Other Accounts Payable 1,581 6,290 - 7,871 Long term loans from banks, net - - 68,020 68,020 Liabilities in respect of leases-LT - - 2,067 2,067 Advanced payments from MDA against future orders - - (28,138 ) (28,138 ) Liability for IIA Royalties - - (1,107 ) (1,107 ) Derivatives Liabilities - - (114 ) (114 ) Total 2,011 28,617 42,728 73,356 December 31, 2022 Within 30 days 1-12 Months 1-5 Years Total Liabilities in respect of leases-ST 269 752 - 1,021 Trade payables 251 1,209 - 1,460 Payables to related parties - - - - Other Accounts Payable 3,534 4,309 - 7,843 Long term loans from banks, net - - 77,543 77,543 Liabilities in respect of leases-LT - - 2,280 2,280 Loan from Shareholder - - - - Derivatives Liabilities - - 20,305 20,305 Total 4,054 6,270 100,128 110,452
Schedule of fair value of financial liabilities	Level December 31, 2023 December 31, 2022 Financial Liabilities: Warrants 3 - - SPAC Public Warrant 1 - 286 SPAC Private Warrant 2 - 121 Advanced payments from MDA against future orders 3 28,138 - Price Adjustment shares 3 114 19,898 Total 28,252 20,305
Derivatives Liabilities
Fair value of financial liabilities
Schedule of changes in fair value of liabilities	Warrants Balance at January 1, 2022 1,392 Exercise of warrants to shares (397 ) Exercise of warrants to cash (adjustment to other accounts payables) (800 ) Changes in fair value recognized in finance expenses (195 ) Balance at December 31, 2022 - Exercise of warrants to shares - Exercise of warrants to cash (adjustment to other accounts payables) - Changes in fair value recognized in finance expenses - Balance at December 31, 2023 -
SPAC Warrant
Fair value of financial liabilities
Schedule of changes in fair value of liabilities	SPAC Warrants Balance at December 31, 2022 407 Issuance of warrant (SPAC transactions) - Changes in fair value recognized in finance expenses (407 ) Exercise of warrants - Balance at December 31, 2023 -
Price adjustment shares
Fair value of financial liabilities
Schedule of changes in fair value of liabilities	PAS Balance on December 31, 2022 19,898 Changes in fair value recognized in finance expenses (19,784 ) Balance on December 31, 2023 114

OTHER LONG-TERM LIABILITIES (Ta

OTHER LONG-TERM LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Other Long Term Liabilities [Abstract]
Schedule of breakdown of other long-term liabilities	December 31, 2023 December 31, 2022 Liability for IIA Royalties (See Note 16(b) below) 1,196 1,107 Alta settlement (See note 19) 300 - 1,496 1,107
Schedule of reconciliation of changes in liability for royalties payable	December 31, 2023 December 31, 2022 At January 1 1,107 1,368 Principal Payments (11 ) (429 ) Amounts recognized as an offset from research and development expenses (113 ) (210 ) Revaluation of the liability 213 378 As of December 31 1,196 1,107

FORWARD PURCHASE AGREEMENT (Tab

FORWARD PURCHASE AGREEMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Forwared Purchase Agreement [Abstract]
Schedule of detailed information about forward purchase agreement explanatory	At January 1, 2022 - FPA (SPAC transactions)- Assets 42,502 FPA (SPAC transactions)- Liability (13,306 ) FPA (SPAC transactions) net 29,196 Revaluation as of 21.11.2022 (36,692 ) Issuance of shares in 21.11.2022 49,998 Revaluation as of 31.12.2022 (1,650 ) As of December 31, 2022 40,852 Cash received (10,026 ) Revaluation as of October 2023 (37,408 ) Termination (6,582 ) As of December 31, 2023 -

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
Schedule of information about share options outstanding and exercisable	Options Outstanding Options Exercisable Number Outstanding on December 31, 2023 (in thousands) Weighted Average Number Exercisable on December 31, 2023 (in thousands) Exercise Price Years USD 768 1.06 768 0.0001 563 0.17 563 0.536 260 4.46 260 0.550 1,162 5.26 1,095 1.102 3,462 7.1 485 2.5 6,215 3,171
Schedule of number and weighted average exercise prices of share options	2023 2022 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price USD USD Options outstanding at the beginning of year: 7,297 1.76 7,710 1.72 Changes during the year: Granted - - 1,405 2.50 Exercised 38 0.68 226 0.42 Forfeited 1,044 2.38 1,592 0.22 Options outstanding at end of year 6,215 1.67 7,297 1.76 Options exercisable at year-end 3,171 0.90 3,169 0.87
Schedule of information about share restricted stock units outstanding and exercisable	Number of RSUs Outstanding at beginning of year - Granted 7,808,280 Vested (902,753 ) Forfeited (1,686,426 ) Unvested as of December 31, 2023 5,219,101

REVENUES (Tables)

REVENUES (Tables)	12 Months Ended
	Dec. 31, 2023
REVENUES
Schedule of revenues from sale of products	For the year ended December 31, 2023 2022 2021 USD thousands % USD thousands % USD thousands % Jet Talk - - - - 3,116 14 % Airbus 188 2 % 318 3 % 3,256 15 % Telesat 4,250 40 % 5,326 50 % 8,400 39 % iDirect 2,605 24 % 489 5 % 2,074 10 % Trustcom - 0 % 1,108 10 % - - MDA 1,497 14 % 1,907 18 % - - Confidential Customer 1,309 12 % 1,162 11 % - - US & Canada UK Other Consolidated 2023 2022 2021 2023 2022 2021 2023 2022 2021 2023 2022 2021 Revenues 8,446 9,310 13,196 732 1,070 7,325 1,552 246 1,199 10,730 10,626 21,720

COST OF SALES AND SERVICES (Tab

COST OF SALES AND SERVICES (Tables)	12 Months Ended
	Dec. 31, 2023
Cost Of Revenue And Service Abstract
Schedule of cost of revenue and service	December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 2,861 3,556 6,764 Materials and models 2,276 707 1,516 Depriciation 34 21 56 Chip Development tools and Subcontractors 767 214 507 Total 5,938 4,498 8,843

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2023
Research And Development Expenses [Abstract]
Schedule of research and development expenses	For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses, including Stock Based Compensation 23,450 21,923 18,810 Chip pre-production and Development tools 9,917 7,214 12,936 Government support and grants (4,241 ) (12,295 ) (13,802 ) Total 29,126 16,842 17,944

SELLING AND MARKETING EXPENSES

SELLING AND MARKETING EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2023
Selling And Marketing Expenses [Abstract]
Schedule of selling and marketing expenses	For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 2,866 2,335 1,752 Total 2,866 2,335 1,752

ADMINISTRATIVE AND GENERAL EX_2

ADMINISTRATIVE AND GENERAL EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2023
Administrative And General Expenses [Abstract]
Schedule of administrative and general expenses	For the year ended December 31, 2023 December 31, 2022 December 31, 2021 Salaries and related expenses 5,925 8,175 3,233 Depreciation and overheads 93 132 240 Expected Credit Loss (a) 1,876 - - Other expenses (b) 6,667 942 262 Total 14,561 9,249 3,735 (a) Write off of a contract asset relating to Jet-Talk contract asset balance, as the Company does not believe it can benefit from the remaining asset due to certain disagreement between the parties, which are under discussion and expected to be resolved in the near future. (b) In 2023 expenses occurred following the Alta settlement of $2.3 million (see Note 19) and new D&O Insurance policy expenses.

LISTING EXPENSES (Tables)

LISTING EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Listing Expenses [Abstract]
Schedule of net assets contributed by EDNCU	Note October 27, 2022 Price Adjustment Shares 212,675 Issuance of shares 149,657 Private Warrants 15 1,681 Public Warrants 15 2,203 PIPE Warrants 15 22 Net Liability of Business Combination 687 Forward Purchase Agreement- Liabilities 17 13,306 380,231 Total Cash (7,813 ) Forward Purchase Agreement- Assets 17 (42,502 ) (50,315 ) Other Listing Expenses 3,410 Total 333,326
Schedule of listing expenses of one-time non-recurring nature	Quantity Price Total Amount Price Adjustment Shares 27,500 7.73 212,575 2 Premium- SPAC shares 14,800 10.11 149,628 3 Warrants 18,630 0.22 4,099 1 Forward Purchase Agreement- Liabilities 1,605 8.29 13,305 1 Forward Purchase Agreement- Assets 42,502 4

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Schedule of loss per share	For the year ended December 31 2023 2022 2021 Calculation of basic earnings per share: Net loss (29,715 ) (397,789 ) (17,050 ) Loss attributed to ordinary shareholders in USD (29,715 ) (397,789 ) (17,050 ) Weighted average number of ordinary shares 80,974,653 30,030,805 18,732,473 Basic and diluted loss per share attributed in USD (0.37 ) (13.25 ) (0.91 )

GENERAL - Narrative (Details)

GENERAL - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
General
Net loss	$ (29,715)	$ (397,789)	$ (17,050)
Accumulated deficit	(511,323)	$ (481,608)
Total consideration	40,000
Advanced payments of future products	20,000
Gross increase in cash	20,000
Cash expenses in cash related transactions	18,700
Amount of ordinary shares issue and sell under business combination agreement	77,250
Aggregate gross proceeds of amount of ordinary shares issue and sell under business combination agreement	$ 75,000

GENERAL - Schedule of ownership

GENERAL - Schedule of ownership percentage of subsidiaries (Details) - Subsidiary	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Subsidiaries
Number of wholly-owned subsidiaries by which Company is primarily operated	5
Israeli subsidiary
Subsidiaries
Holding percentage	100%	100%
Satixfy UK
Subsidiaries
Holding percentage	100%	100%
Satixfy Satellite Systems UK
Subsidiaries
Holding percentage	0%	100%
Satixfy Bulgaria
Subsidiaries
Holding percentage	100%	100%
Satixfy US LLC
Subsidiaries
Holding percentage	100%	100%
Endurance Acquisition Corporation
Subsidiaries
Holding percentage	100%	100%

GENERAL - Schedule of holding p

GENERAL - Schedule of holding percentage of joint venture agreement (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Jet talk Limited (“Jet-Talk”)
Joint venture agreement
Holding percentage	51%	51%

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)	Dec. 31, 2023
SIGNIFICANT ACCOUNTING POLICIES
Weighted-average rate applied measured at an amount equal to the lease liability	4.50%

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property, plant and equipment (Details)	12 Months Ended
	Dec. 31, 2023
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	33.30%
Leasehold Improvement | Minimum
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	25%	[1]
Leasehold Improvement | Maximum
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	33%	[1]
Furniture
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	15%
Machinery and Equipment | Minimum
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	7%
Machinery and Equipment | Maximum
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rate	14%
[1]In case that the duration of the lease contract is less than the lease improvement, the depreciation is being made over the contract’s period.

MDA AGREEMENT - Schedule of Mda

MDA AGREEMENT - Schedule of Mda agreement Narrative (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total consideration			$ 40,000
Proceeds From Private Investment In Public Equity			20,000
Promissory Notes			$ 20,000	$ 0
Interest per annum of pre purchase agreement			12%
Promissory Notes
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total consideration			$ 37,000
Consideration to be paid			17,000
Consideration remaining balance			20,000
Monthly instalments balance			2,850
MDA Agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Company announced transaction value	$ 60,000
Total consideration	40,000
Proceeds From Private Investment In Public Equity	$ 20,000	$ 10,000
Share Purchase Agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total consideration			40,000
Consideration to be paid			1,000
Consideration remaining balance			2,000
Satixfy Space Systems
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total consideration			3,000
Pre Purchase Agreement
Disclosure of disaggregation of revenue from contracts with customers [line items]
Consideration to be paid			10,000
Consideration remaining balance			5,000
Additional consideration payment value			$ 15,000

CONTRACT ASSETS - Schedule of c

CONTRACT ASSETS - Schedule of contract assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Contract assets [abstract]
Related parties	$ 0	$ 1,679
Other trade receivables	4,091	3,356
Contract Assets	$ 4,091	$ 5,035	$ 6,015

CONTRACT ASSETS - Schedule of_2

CONTRACT ASSETS - Schedule of contract assets, revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract assets [abstract]
Balance at the beginning of the year	$ 5,035	$ 6,015
Revenue recognition in the period, net	643	(426)
Provisions	(1,876)	0
Currency translation adjustments	289	(554)
Balance at the end of the year	$ 4,091	$ 5,035

INVENTORY - Schedule of invento

INVENTORY - Schedule of inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Classes of current inventories [abstract]
Raw materials	$ 1,397	$ 817
Finished goods inventory	78	14
Inventory	$ 1,475	$ 831

LEASE LIABILITIES AND RIGHT O_3

LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 Agreement
Buildings [member]
Right of use assets
Term of lease agreement	5 years
Vehicles [Member]
Right of use assets
Term of lease agreement	3 years
Bulgaria
Right of use assets
Number of agreements expires	2

LEASE LIABILITIES AND RIGHT O_4

LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET - Schedule of carried value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Right of use assets
Balance at Beginning of period	$ 2,794
Balance at End of period	2,235	$ 2,794
Buildings [member]
Right of use assets
Balance at Beginning of period	2,662
Balance at End of period	2,121	2,662
Cars [Member]
Right of use assets
Balance at Beginning of period	132
Balance at End of period	114	132
Cost
Right of use assets
Balance at Beginning of period	5,073	5,376
Additions	765	590
Disposals	(1,815)	(893)
Balance at End of period	4,023	5,073	$ 5,376
Cost | Buildings [member]
Right of use assets
Balance at Beginning of period	4,918	4,918	5,294
Additions	662		434
Disposals	(1,741)		(810)
Balance at End of period	3,839	4,918	4,918
Cost | Cars [Member]
Right of use assets
Balance at Beginning of period	155	82
Additions	103	156
Disposals	(74)	(83)
Balance at End of period	184	155	82
Accumulated Depreciation
Right of use assets
Balance at Beginning of period	(2,279)	(2,229)
Additions	(999)	(943)
Disposals	1,490	893
Balance at End of period	(1,788)	(2,279)	(2,229)
Accumulated Depreciation | Buildings [member]
Right of use assets
Balance at Beginning of period	(2,256)		(2,155)
Additions	(916)		(911)
Disposals	1,454		810
Balance at End of period	(1,718)	(2,256)
Accumulated Depreciation | Cars [Member]
Right of use assets
Balance at Beginning of period	(23)	(74)
Additions	(83)	(32)
Disposals	36	83
Balance at End of period	$ (70)	$ (23)	$ (74)

LEASE LIABILITIES AND RIGHT O_5

LEASE LIABILITIES AND RIGHT OF USE ASSETS, NET - Schedule of lease transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
LEASE LIABILITIES AND RIGHT OF USE ASSETS
Interest expenses in respect of lease liabilities	$ 337	$ 393
Lease principal payments during the year	$ 927	$ 1,029

INVESTMENT IN JET-TALK - Narrat

INVESTMENT IN JET-TALK - Narrative (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2018 USD ($) Agreement	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
INVESTMENT IN JET TALK
Investment made		$ 1,551	$ 1,777
Revenues		$ 10,730	$ 10,626	$ 21,720
Jet talk Limited (“Jet-Talk”)
INVESTMENT IN JET TALK
Ownership interest held		51%	51%
Jet talk Limited (“Jet-Talk”) | STE
INVESTMENT IN JET TALK
Investment made	$ 20,000
Ownership interest held	49%
Jet talk Limited (“Jet-Talk”) | Satixfy UK Limited
INVESTMENT IN JET TALK
Revenues		$ 13,000
Number of development agreements signed | Agreement	2
Ownership interest held	51%	51%

INVESTMENT IN JET-TALK - Schedu

INVESTMENT IN JET-TALK - Schedule of condensed information of Jet talk (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
INVESTMENT IN JET TALK
Revenues	$ 10,730	$ 10,626	$ 21,720
Net loss	(29,715)	(397,789)	(17,050)
Company's share in the loss of a company accounted by equity method, net	(226)	(360)	(1,898)
Jet talk Limited (“Jet-Talk”)
INVESTMENT IN JET TALK
Net loss	442	705	3,722
Company's share in the loss of a company accounted by equity method, net	$ 226	$ 360	$ 1,898

CONTRACT LIABILITIES (Details)

CONTRACT LIABILITIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract liabilities [abstract]
Balance at the beginning of the year	$ 622	$ 475
Expenses recognition in the period, net	819	540
Currency translation adjustments	279	(393)
Balance at the end of the year	$ 1,720	$ 622

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, plant and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	$ 1,643
Balance, end of period	1,420	$ 1,643
Depreciation expenses	308	219
Computers
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	260
Balance, end of period	205	260
Leasehold improvements
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	338
Balance, end of period	243	338
Furniture
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	185
Balance, end of period	161	185
Machinery And Equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	860
Balance, end of period	811	860
Cost
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	3,082	2,192
Additions	235	890
Disposal -SSS sale	(185)
Balance, end of period	3,132	3,082
Cost | Computers
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	1,092	956
Additions	113	136
Disposal -SSS sale	(13)
Balance, end of period	1,192	1,092
Cost | Leasehold improvements
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	600	477
Additions	52	123
Disposal -SSS sale	(119)
Balance, end of period	533	600
Cost | Furniture
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	347	345
Additions	5	2
Disposal -SSS sale	0
Balance, end of period	352	347
Cost | Machinery And Equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	1,043	414
Additions	65	629
Disposal -SSS sale	(53)
Balance, end of period	1,055	1,043
Accumulated Depreciation
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	(1,439)	(1,220)
Additions	(308)	(219)
Disposal -SSS sale	35
Balance, end of period	(1,712)	(1,439)
Accumulated Depreciation | Computers
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	(832)	(714)
Additions	(156)	(118)
Disposal -SSS sale	1
Balance, end of period	(987)	(832)
Accumulated Depreciation | Leasehold improvements
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	(262)	(212)
Additions	(62)	(50)
Disposal -SSS sale	34
Balance, end of period	(290)	(262)
Accumulated Depreciation | Furniture
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	(162)	(138)
Additions	(29)	(24)
Disposal -SSS sale	0
Balance, end of period	(191)	(162)
Accumulated Depreciation | Machinery And Equipment
PROPERTY, PLANT AND EQUIPMENT, NET
Balance, beginning of period	(183)	(156)
Additions	(61)	(27)
Disposal -SSS sale	0
Balance, end of period	$ (244)	$ (183)

OTHER ACCOUNTS PAYABLE AND AC_3

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Schedule of other accounts payable and accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Accounts Payable And Accrued Expenses [Abstract]
Liabilities in respect of employees, wages and institutions in respect of wages	$ 2,584	$ 3,023
Accrued expenses	6,849	4,607
Liabilities to government institutions due to grants received	136	161
Tax accrual	122	0
Government departments and agencies	13	52
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	$ 9,704	$ 7,843

LONG TERM LOANS FROM FINANCIA_3

LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET - Narrative (Details)

1 Months Ended

12 Months Ended

Feb. 01, 2022 USD ($) Percent shares

Apr. 23, 2023 USD ($)

Oct. 27, 2022 USD ($) shares

Jul. 31, 2022 USD ($)

Apr. 30, 2021 USD ($)

Sep. 30, 2020

Apr. 30, 2020

Mar. 31, 2020 USD ($) Portion

May 31, 2019 USD ($) Portion

Jul. 31, 2016 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Jun. 30, 2023 USD ($) shares

May 31, 2023 USD ($)

Apr. 30, 2023 USD ($)

Aug. 31, 2021 USD ($)

Long Term Loan

Loan amount

$ 5,000,000

$ 2,300,000

Loan term

30 months

Warrants term

8 years

Warrant exercised (in shares) | shares

6,520

Repayments of borrowings

$ 0

$ 5,000,000

$ 0

Credit agreement description

i) provided a waiver of certain defaults or potential defaults, (ii) permitted the Company to make its interest payments for 2023 on a pay-in-kind basis if its cash balance is less than $12.5 million, (iii) temporarily reduced the Company’s minimum cash requirement from $10 million to $8 million and $7 million for the months of April and May 2023, respectively, and thereafter to $10 million, in each case plus an amount sufficient to cover its and its subsidiaries’ accounts payable that are past 60 days due, (iv) increased the interest rate of the loan to Secured Overnight Financing Rate (“SOFR”) + 9.50% (with a 3% SOFR floor) and (v) provided for certain additional reporting obligations by the Company.

Finance Income

83,000

$ 17,000

$ 0

MDA Agreement

Long Term Loan

Minimum cash

$ 10,000,000

Prepayment Amount

10,000,000

Number of shares issued | shares

5,100,000

Finance Income

2,500,000

MDA Agreement | Private Placements [Member]

Long Term Loan

Number of shares issued | shares

1,000,000

Risk Free Interest Rate

Long Term Loan

Debt instrument measurement input | Percent

1.16

Expected volatility rate

Long Term Loan

Debt instrument measurement input | Percent

50

Preferred Shares B

Long Term Loan

Warrant exercised

$ 57,659

Israeli subsidiary

Long Term Loan

Loan term

5 years

5 years

Interest rate adjustment (as a percent)

1.50%

1.50%

First loan | Israeli subsidiary

Long Term Loan

Loan amount

$ 2,000,000

Loan term

36 months

Interest rate adjustment (as a percent)

6.90%

Warrants term

6 years

Second loan | Israeli subsidiary

Long Term Loan

Loan amount

$ 3,000,000

$ 5,000,000

Number of loans portions | Portion

2

2

Loan term

36 months

36 months

Warrants term

10 years

10 years

State-guaranteed bank loan | Israeli subsidiary

Long Term Loan

Waiver of alternative payment

$ 800,000

$ 800,000

Long Term Loan | Francisco Partners L.P

Long Term Loan

Loan amount received

$ 55,000,000

Qualified Public Offering Term

12 months

Interest rate (as a percent)

9.5

Basis points of increase in interest rate

100

Pay in kind interest payable company completes QPO (as a percent)

100%

PIK interest

$ 3,988,000

Shares issued | shares

808,907

Repayments of borrowings

$ 19,100,000

Repayment of debt to shareholder

5,300,000

Repayment of debt to financial institutions

13,800,000

Fair value of loan

50,073,000

Long Term Loan | Francisco Partners L.P | Level 3

Long Term Loan

Issuance shares

$ 1,978

Long Term Loan | Francisco Partners L.P | Year one

Long Term Loan

Pay in kind interest payable (as a percent)

100%

Long Term Loan | Francisco Partners L.P | Year Two

Long Term Loan

Pay in kind interest payable (as a percent)

75%

Long Term Loan | Francisco Partners L.P | Thereafter

Long Term Loan

Pay in kind interest payable (as a percent)

50%

Long Term Loan | Francisco Partners L.P | Minimum

Long Term Loan

Loan term

2 years 6 months

Long Term Loan | Francisco Partners L.P | Maximum

Long Term Loan

Loan term

4 years

Interest rate adjustment (as a percent)

11.50%

Credit Agreement

Long Term Loan

Cash balance

$ 12,500,000

$ 10,000,000

$ 7,000,000

$ 8,000,000

Minimum cash

$ 10,000,000

Credit Agreement | Minimum

Long Term Loan

Secured overnight financing rate

3%

Credit Agreement | Maximum

Long Term Loan

Secured overnight financing rate

9.50%

LONG TERM LOANS FROM FINANCIA_4

LONG TERM LOANS FROM FINANCIAL INSTITUTIONS, NET - Schedule of loans at balance sheet date (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
LOAN FROM SHAREHOLDER
Long term loans from financial institutions, net	$ 59,792	$ 54,926

LOAN FROM SHAREHOLDER_ Narrativ

LOAN FROM SHAREHOLDER: Narrative (Details) - USD ($) $ in Millions	1 Months Ended			12 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Mar. 31, 2020	Dec. 31, 2023	Aug. 31, 2021
Disclosure of detailed information about borrowings [line items]
Loan amount		$ 5			$ 2.3
Loan term		30 months
Shareholder
Disclosure of detailed information about borrowings [line items]
Loan amount			$ 5
Loan term			36 months
Proceeds from life insurance	$ 5.4
Shareholder | Mr. Yoel Gat [Member]
Disclosure of detailed information about borrowings [line items]
Amount of insurance policy taken as guarantee				$ 5

RELATED PARTIES - Narrative (De

RELATED PARTIES - Narrative (Details)

1 Months Ended

12 Months Ended

20 Months Ended

Dec. 24, 2020 USD ($)

Feb. 14, 2020 USD ($) Agreement

Feb. 06, 2018 USD ($) Agreement

May 04, 2017

Oct. 19, 2023 USD ($)

Apr. 30, 2023 USD ($)

Sep. 15, 2022 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Dec. 31, 2018 USD ($)

RELATED PARTIES:

Number of options to purchase shares approved

0

1,405

Separation Agreement

RELATED PARTIES:

Description of compensation payment

(i) five monthly payments in the gross sum of $55,000 plus VAT from May through September 2023; (ii) one monthly payment of $110,000 plus VAT in October 2023, totaling in the aggregate, $385,000 plus VAT; and (iii) other customary terms and conditions.

(i) grant Mr. Leibovitch a $2 million success bonus payable upon the Closing of the Business Combination, (ii) increase Mr. Leibovitch’s monthly fee for services provided to $100,000 per month, effective as of October 1, 2022, increase Mr. Leibovitch’s yearly bonus such that the yearly bonus shall be 2% of the incremental year-over-year growth of the shareholders’ equity in the consolidated financial statements of the Company and increase Mr. Leibovitch’s annual bonus such that the annual bonus shall be 2% of the incremental year- over-year growth of revenues in the consolidated financial statements of the Company.

Total monthly payments in gross

$ 55,000,000

Fist monthly payment

110,000,000

Aggregate total of payment

$ 385,000,000

Success bonus payable of business combination

$ 2,000

Services provided related party transactions

$ 100,000,000

Percentage of yearly bonus

2%

Aggregate special success bonus

$ 1,000,000

Ilan Gat Engineers Ltd | Service agreement with related parties

RELATED PARTIES:

Amount of monthly compensation

$ 110,000

$ 100,000

$ 50,000

Description of management fees

According to this agreement, as of 2018, the management fees were paid to Ilan Gat, which consists of a monthly management fee of $50 and reimbursement of other monthly expenses for the services of Yoel Gat and Simona Gat, the former President and former COO of the Company. In November 2019 the Company’s board of directors approved a retroactive update of the monthly management fee starting in January 2019 to the amount of $100 and reimbursement of other monthly expenses.In January 2021 the Company’s board of directors approved an update of the monthly management fee starting in January 2021 to the amount of $110 and reimbursement of other monthly expenses and a yearly bonus of 0.67% for Yoel Gat’s services and 0.67% for Simona Gat’s services out of the incremental year to year growth in Equity in the consolidated financial statements of the Company effective 2021 and Annual Bonus of 0.67% for Yoel Gat’s services and 0.67% for Simona Gat’s services out of the incremental year to year growth in revenues of the Company each year effective 2021. On December 24th, 2020 and on January 4th, 2021 the board and the shareholders, respectively approved the grant of 1.3 million options to Yoel Gat and 1.3 million options to Ms. Simona Gat to purchase ordinary shares of the Company according to the 2020 Share Award Plan.

Mr. Yoel Gat | Service agreement with related parties

RELATED PARTIES:

Number of options to purchase shares approved

1,300,000

Ms. Simona Gat | Service agreement with related parties

RELATED PARTIES:

Number of options to purchase shares approved

1,300,000

Jet talk Limited (“Jet-Talk”) | Development agreements with related parties

RELATED PARTIES:

Number of development agreements | Agreement

3

3

Total consideration to provide an electronically steerable Panel Antenna Array ("PAA") and supporting modem

$ 32,000,000

$ 32,000,000

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Nir Barkan
Disclosure of transactions between related parties
Holding Rate	0.25%
Salary, bonuses and related expenses	$ 303
Expected Bonus	160
Share-Based Payments	$ 129
Ilan Gat (Simona Gat)
Disclosure of transactions between related parties
Holding Rate	19.47%	19.80%
Salary, bonuses and related expenses	$ 605	$ 660
Expected Bonus	0	40
Share-Based Payments	$ 39	$ 39
Raysat (Yoav Leibovitch)
Disclosure of transactions between related parties
Holding Rate	26.35%	27.04%
Salary, bonuses and related expenses	$ 1,750	$ 5,065
Expected Bonus	450	60
Share-Based Payments	$ 39	$ 39

RELATED PARTIES - Schedule of

RELATED PARTIES - Schedule of transactions with related parties (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Revenues from ST Engineering iDirect ("iDirect")
Disclosure of transactions between related parties [line items]
Revenues	[1]	$ 2,065	$ 489
[1]iDirect is a shareholder of the Company and after SPAC transaction iDirect is no longer a related party due to their decreased holding.

RELATED PARTIES_ - Outstanding

RELATED PARTIES: - Outstanding balances with related parties (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Total Assets	$ 75	$ 1,836
Liabilities
Total Liabilities	740	408
Contract assets (Jet Talk)
ASSETS
Total Assets	0	1,679
Raysat Israel Ltd.
Liabilities
Total Liabilities	550	160
Ilan Gat Engineers Ltd
Liabilities
Total Liabilities	0	95
Former CEO
Liabilities
Total Liabilities	0	100
Current CEO
Liabilities
Total Liabilities	190	0
Jet talk Limited (“Jet-Talk”)
ASSETS
Total Assets	75	157
Liabilities
Total Liabilities	$ 0	$ 53

FINANCIAL INSTRUMENTS - RISK _3

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Narrative (Details) - USD ($)			1 Months Ended	12 Months Ended
	Dec. 11, 2022	Dec. 08, 2022	Oct. 27, 2022	Dec. 31, 2023	Dec. 31, 2022
Financial Instruments [Line Items]
Value of new warrants			$ 3,906,000
Warrant equity			3,490,000
Warrant liability			$ 416,000
Marked price of warrants derivatives			$ 0.22
Expected exercise period				9 years 10 months 13 days
Price adjustment shares
Financial Instruments [Line Items]
Number of shares issued				27,500,000
Description of vesting requirements				The Price Adjustment Shares vest upon three price adjustment achievement dates: (i) one-third of the Price Adjustment Shares will vest if at any time forty-five (45) days after the date of effectiveness of the applicable registration statement (File no. 333-268510) and within the 10-year period following the closing, the volume weighted average price (“VWAP”) of SatixFy Ordinary Shares is greater than or equal to $12.50 for any seven (7) trading days within a period of 30 consecutive trading days, (ii) one-third of the Price Adjustment Shares will vest if at any time forty-five (45) days after the date of effectiveness of the applicable registration statement (File no. 333-268510) and within the 10-year period following the closing, the VWAP of SatixFy Ordinary Shares is greater than or equal to $14.00 for any seven (7) trading days within a period of 30 consecutive trading days and one-third of the Price Adjustment Shares will vest if at any time forty-five (45) days after the date of effectiveness of the applicable registration statement (File no. 333-268510) and within the 10-year period following the closing, the VWAP of SatixFy Ordinary Shares is greater than or equal to $15.50 for any seven (7) trading days within a period of 30 consecutive trading days.
Description of influence of change in control transaction on price adjustment shares				In the event of a SatixFy change in control transaction within ten (10) years following the closing of the Business Combination, all of the unvested Price Adjustment Shares not earlier vested will vest immediately prior to the closing of such change in control. If the Price Adjustment Shares do not vest according to the achievement dates in the Business Combination Agreement, or if a change of control has not occurred after the Closing and prior to the date that is ten (10) years following the Closing Date, then any unvested Price Adjustment Shares shall automatically be forfeited back to SatixFy for no consideration.
Value of shares issued				$ 212,675,000
Total value of Equity shares under derivatives				191,132,000
Total value of liability shares under derivatives				$ 21,543,000
Risk-free rate			3.96%	3.88%
Expected exercise period			10 years 4 months 1 day	9 years 23 days	10 years 1 month 28 days
Expected volatility (as a percent)			50%	50%
Weighted average share price			$ 7.73	$ 0.3631	$ 7.14
Price adjustment shares | Founders
Financial Instruments [Line Items]
Number of shares issued				27,000,000
Price adjustment shares | Yoav Leibovitch
Financial Instruments [Line Items]
Number of shares issued				18,000,000
Price adjustment shares | Simona Gat
Financial Instruments [Line Items]
Number of shares issued				9,000,000
SPAC public warrant
Financial Instruments [Line Items]
Number of new warrants exercised		3,364,000
Number of shares issued		553,692
Pipe warrant
Financial Instruments [Line Items]
Number of new warrants exercised	935,000
Proceeds from of warrants	$ 1,500
Number of shares issued	2,000,000
Business combination agreement SPAC transaction [Member] | SPAC private warrant
Financial Instruments [Line Items]
Number of new warrants issued				7,630,000
Business combination agreement SPAC transaction [Member] | SPAC public warrant
Financial Instruments [Line Items]
Number of new warrants issued				10,000,000
Business combination agreement SPAC transaction [Member] | Pipe warrant
Financial Instruments [Line Items]
Number of new warrants issued				1,000,000

FINANCIAL INSTRUMENTS - RISK _4

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of credit risk (Details) - Credit risk - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Credit risk
Maximum exposure to credit risk	$ 44,383	$ 61,282
Cash
Credit risk
Maximum exposure to credit risk	13,979	11,934
Trade accounts receivables
Credit risk
Maximum exposure to credit risk	2,260	1,295
Other accounts receivable
Credit risk
Maximum exposure to credit risk	2,053	2,166
Promissory Notes
Credit risk
Maximum exposure to credit risk	20,000	0
Other long term receivables
Credit risk
Maximum exposure to credit risk	2,000	0
FPA
Credit risk
Maximum exposure to credit risk	0	40,852
Contract assets
Credit risk
Maximum exposure to credit risk	$ 4,091	$ 5,035

FINANCIAL INSTRUMENTS - RISK _5

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of currency risk (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
NIS
Risk management
Exposure to risk	$ (3,478)	$ (5,344)
EUR
Risk management
Exposure to risk	2,477	1,710
GBP
Risk management
Exposure to risk	(975)	2,936
Currency risk
Risk management
Exposure to risk	(56,698)	(7,140)
Currency risk | NIS
Risk management
Exposure to risk	(3,478)	(5,344)
Currency risk | EUR
Risk management
Exposure to risk	2,477	1,710
Currency risk | GBP
Risk management
Exposure to risk	(975)	2,936
Currency risk | USD
Risk management
Exposure to risk	(54,722)	(6,442)
Currency risk | Cash and cash equivalents
Risk management
Exposure to risk	13,979	11,934
Currency risk | Cash and cash equivalents | NIS
Risk management
Exposure to risk	1,120	1,281
Currency risk | Cash and cash equivalents | EUR
Risk management
Exposure to risk	1,372	640
Currency risk | Cash and cash equivalents | GBP
Risk management
Exposure to risk	235	607
Currency risk | Cash and cash equivalents | USD
Risk management
Exposure to risk	11,252	9,406
Currency risk | Trade receivables
Risk management
Exposure to risk	2,260	1,295
Currency risk | Trade receivables | NIS
Risk management
Exposure to risk	0	0
Currency risk | Trade receivables | EUR
Risk management
Exposure to risk	55	187
Currency risk | Trade receivables | GBP
Risk management
Exposure to risk	0	804
Currency risk | Trade receivables | USD
Risk management
Exposure to risk	2,205	304
Currency risk | Prepaid expenses and other account receivables
Risk management
Exposure to risk	2,053	2,166
Currency risk | Prepaid expenses and other account receivables | NIS
Risk management
Exposure to risk		0
Currency risk | Prepaid expenses and other account receivables | EUR
Risk management
Exposure to risk	2,036	2,149
Currency risk | Prepaid expenses and other account receivables | GBP
Risk management
Exposure to risk		0
Currency risk | Prepaid expenses and other account receivables | USD
Risk management
Exposure to risk	17	17
Currency risk | Promissory Notes
Risk management
Exposure to risk	20,000
Currency risk | Promissory Notes | NIS
Risk management
Exposure to risk	0
Currency risk | Promissory Notes | EUR
Risk management
Exposure to risk	0
Currency risk | Promissory Notes | GBP
Risk management
Exposure to risk	0
Currency risk | Promissory Notes | USD
Risk management
Exposure to risk	20,000
Currency risk | Other long term receivables
Risk management
Exposure to risk	2,000
Currency risk | Other long term receivables | NIS
Risk management
Exposure to risk	0
Currency risk | Other long term receivables | EUR
Risk management
Exposure to risk	0
Currency risk | Other long term receivables | GBP
Risk management
Exposure to risk	0
Currency risk | Other long term receivables | USD
Risk management
Exposure to risk	2,000
Currency risk | Derivatives FPA
Risk management
Exposure to risk		40,852
Currency risk | Derivatives FPA | NIS
Risk management
Exposure to risk		0
Currency risk | Derivatives FPA | EUR
Risk management
Exposure to risk		0
Currency risk | Derivatives FPA | GBP
Risk management
Exposure to risk		0
Currency risk | Derivatives FPA | USD
Risk management
Exposure to risk		40,852
Currency risk | Contract assets
Risk management
Exposure to risk	4,091	5,035
Currency risk | Contract assets | NIS
Risk management
Exposure to risk	0	0
Currency risk | Contract assets | EUR
Risk management
Exposure to risk	0	0
Currency risk | Contract assets | GBP
Risk management
Exposure to risk	128	3,720
Currency risk | Contract assets | USD
Risk management
Exposure to risk	3,963	1,315
Currency risk | Financial assets
Risk management
Exposure to risk	44,383	61,282
Currency risk | Financial assets | NIS
Risk management
Exposure to risk	1,120	1,281
Currency risk | Financial assets | EUR
Risk management
Exposure to risk	3,463	2,976
Currency risk | Financial assets | GBP
Risk management
Exposure to risk	363	5,131
Currency risk | Financial assets | USD
Risk management
Exposure to risk	39,437	51,894
Currency risk | Current maturities long-term loans
Risk management
Exposure to risk	0	0
Currency risk | Current maturities long-term loans | NIS
Risk management
Exposure to risk	0	0
Currency risk | Current maturities long-term loans | EUR
Risk management
Exposure to risk		0
Currency risk | Current maturities long-term loans | GBP
Risk management
Exposure to risk	0	0
Currency risk | Current maturities long-term loans | USD
Risk management
Exposure to risk	0	0
Currency risk | Liabilities in respect of leases-ST
Risk management
Exposure to risk	(639)
Currency risk | Liabilities in respect of leases-ST | NIS
Risk management
Exposure to risk	(469)	0
Currency risk | Liabilities in respect of leases-ST | EUR
Risk management
Exposure to risk	0
Currency risk | Liabilities in respect of leases-ST | GBP
Risk management
Exposure to risk	(144)	(591)
Currency risk | Liabilities in respect of leases-ST | USD
Risk management
Exposure to risk	(26)	0
Currency risk | Long Term Liabilities In Respect Of Leases-st [Member]
Risk management
Exposure to risk	(2,067)	(2,280)
Currency risk | Long Term Liabilities In Respect Of Leases-st [Member] | NIS
Risk management
Exposure to risk	(1,558)	(1,830)
Currency risk | Long Term Liabilities In Respect Of Leases-st [Member] | EUR
Risk management
Exposure to risk	0	0
Currency risk | Long Term Liabilities In Respect Of Leases-st [Member] | GBP
Risk management
Exposure to risk	(495)	(450)
Currency risk | Long Term Liabilities In Respect Of Leases-st [Member] | USD
Risk management
Exposure to risk	(14)	0
Currency risk | Advanced payments from MDA against future orders
Risk management
Exposure to risk	(28,138)	(1,021)
Currency risk | Advanced payments from MDA against future orders | NIS
Risk management
Exposure to risk	0	(430)
Currency risk | Advanced payments from MDA against future orders | GBP
Risk management
Exposure to risk	0
Currency risk | Advanced payments from MDA against future orders | USD
Risk management
Exposure to risk	(28,138)
Currency risk | Trade payables
Risk management
Exposure to risk	(1,378)	(1,459)
Currency risk | Trade payables | NIS
Risk management
Exposure to risk	(479)	(614)
Currency risk | Trade payables | EUR
Risk management
Exposure to risk	(368)	(324)
Currency risk | Trade payables | GBP
Risk management
Exposure to risk	(284)	(433)
Currency risk | Trade payables | USD
Risk management
Exposure to risk	(247)	(88)
Currency risk | Payables and credit balances
Risk management
Exposure to risk	(7,871)	(7,629)
Currency risk | Payables and credit balances | NIS
Risk management
Exposure to risk	(896)	(2,644)
Currency risk | Payables and credit balances | EUR
Risk management
Exposure to risk	(618)	(942)
Currency risk | Payables and credit balances | GBP
Risk management
Exposure to risk	(415)	(721)
Currency risk | Payables and credit balances | USD
Risk management
Exposure to risk	(5,942)	(3,322)
Currency risk | Current financial liabilities
Risk management
Exposure to risk	(38,026)	(10,109)
Currency risk | Current financial liabilities | NIS
Risk management
Exposure to risk	(1,844)	(3,688)
Currency risk | Current financial liabilities | EUR
Risk management
Exposure to risk	(986)	(1,266)
Currency risk | Current financial liabilities | GBP
Risk management
Exposure to risk	(843)	(1,745)
Currency risk | Current financial liabilities | USD
Risk management
Exposure to risk	(34,535)	(3,410)
Currency risk | Liability for IIA Royalties
Risk management
Exposure to risk	(1,196)	(1,107)
Currency risk | Liability for IIA Royalties | NIS
Risk management
Exposure to risk	(1,196)	(1,107)
Currency risk | Liability for IIA Royalties | EUR
Risk management
Exposure to risk	0	0
Currency risk | Liability for IIA Royalties | GBP
Risk management
Exposure to risk	0	0
Currency risk | Liability for IIA Royalties | USD
Risk management
Exposure to risk	0	0
Currency risk | Long term loans from banks
Risk management
Exposure to risk	(59,792)	(54,926)
Currency risk | Long term loans from banks | NIS
Risk management
Exposure to risk	0	0
Currency risk | Long term loans from banks | EUR
Risk management
Exposure to risk	0	0
Currency risk | Long term loans from banks | GBP
Risk management
Exposure to risk	0	0
Currency risk | Long term loans from banks | USD
Risk management
Exposure to risk	$ 59,792	$ 54,926

FINANCIAL INSTRUMENTS - RISK _6

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of sensitivity analysis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Risk management
Percent increase in risk assumption	10%	10%
Percent decrease in risk assumption	10%
NIS
Risk management
Percent increase in risk assumption	10%	10%
Increase (decrease) in equity and profit and loss	$ (3,478)	$ (5,344)
Increase (decrease) in equity and profit and loss	$ (348)	$ (534)
EUR
Risk management
Percent increase in risk assumption	10%	10%
Increase (decrease) in equity and profit and loss	$ 2,477	$ 1,710
Increase (decrease) in equity and profit and loss	248	170
GBP
Risk management
Increase (decrease) in equity and profit and loss	(975)	2,936
Increase (decrease) in equity and profit and loss	$ (97)	$ 294

FINANCIAL INSTRUMENTS - RISK _7

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of liquidity risks (Details) - Liquidity risk - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Risk management
Undiscounted cash flows	$ 73,356	$ 110,452
Liabilities in respect of leases-ST
Risk management
Undiscounted cash flows	639	1,021
Trade payables
Risk management
Undiscounted cash flows	1,378	1,460
Promissory Notes
Risk management
Undiscounted cash flows	20,000
Other long term receivables
Risk management
Undiscounted cash flows	2,000
Payables to related parties
Risk management
Undiscounted cash flows	740	0
Other Accounts Payable
Risk management
Undiscounted cash flows	7,871	7,843
Long term loans from banks
Risk management
Undiscounted cash flows	68,020	77,543
Liabilities in respect of leases-LT
Risk management
Undiscounted cash flows	2,067	2,280
Loan from Shareholder
Risk management
Undiscounted cash flows		0
Advanced payments from MDA against future orders
Risk management
Undiscounted cash flows	(28,138)
Liability for IIA Royalties
Risk management
Undiscounted cash flows	(1,107)
Derivatives Liabilities
Risk management
Undiscounted cash flows	(114)	20,305
Within 30 days
Risk management
Undiscounted cash flows	2,011	4,054
Within 30 days | Liabilities in respect of leases-ST
Risk management
Undiscounted cash flows	172	269
Within 30 days | Trade payables
Risk management
Undiscounted cash flows	258	251
Within 30 days | Promissory Notes
Risk management
Undiscounted cash flows	0
Within 30 days | Other long term receivables
Risk management
Undiscounted cash flows	0
Within 30 days | Payables to related parties
Risk management
Undiscounted cash flows	0	0
Within 30 days | Other Accounts Payable
Risk management
Undiscounted cash flows	1,581	3,534
Within 30 days | Long term loans from banks
Risk management
Undiscounted cash flows	0	0
Within 30 days | Liabilities in respect of leases-LT
Risk management
Undiscounted cash flows	0	0
Within 30 days | Loan from Shareholder
Risk management
Undiscounted cash flows		0
Within 30 days | Advanced payments from MDA against future orders
Risk management
Undiscounted cash flows	0
Within 30 days | Liability for IIA Royalties
Risk management
Undiscounted cash flows	0
Within 30 days | Derivatives Liabilities
Risk management
Undiscounted cash flows	0	0
Year one
Risk management
Undiscounted cash flows	28,617	6,270
Year one | Liabilities in respect of leases-ST
Risk management
Undiscounted cash flows	467	752
Year one | Trade payables
Risk management
Undiscounted cash flows	1,120	1,209
Year one | Promissory Notes
Risk management
Undiscounted cash flows	20,000
Year one | Other long term receivables
Risk management
Undiscounted cash flows	0
Year one | Payables to related parties
Risk management
Undiscounted cash flows	740	0
Year one | Other Accounts Payable
Risk management
Undiscounted cash flows	6,290	4,309
Year one | Long term loans from banks
Risk management
Undiscounted cash flows	0	0
Year one | Liabilities in respect of leases-LT
Risk management
Undiscounted cash flows	0	0
Year one | Loan from Shareholder
Risk management
Undiscounted cash flows		0
Year one | Advanced payments from MDA against future orders
Risk management
Undiscounted cash flows	0
Year one | Liability for IIA Royalties
Risk management
Undiscounted cash flows	0
Year one | Derivatives Liabilities
Risk management
Undiscounted cash flows	0	0
1-5 years
Risk management
Undiscounted cash flows	42,728	100,128
1-5 years | Liabilities in respect of leases-ST
Risk management
Undiscounted cash flows	0	0
1-5 years | Trade payables
Risk management
Undiscounted cash flows	0	0
1-5 years | Promissory Notes
Risk management
Undiscounted cash flows	0
1-5 years | Other long term receivables
Risk management
Undiscounted cash flows	2,000
1-5 years | Payables to related parties
Risk management
Undiscounted cash flows	0	0
1-5 years | Other Accounts Payable
Risk management
Undiscounted cash flows	0	0
1-5 years | Long term loans from banks
Risk management
Undiscounted cash flows	68,020	77,543
1-5 years | Liabilities in respect of leases-LT
Risk management
Undiscounted cash flows	2,067	2,280
1-5 years | Loan from Shareholder
Risk management
Undiscounted cash flows		0
1-5 years | Advanced payments from MDA against future orders
Risk management
Undiscounted cash flows	(28,138)
1-5 years | Liability for IIA Royalties
Risk management
Undiscounted cash flows	(1,107)
1-5 years | Derivatives Liabilities
Risk management
Undiscounted cash flows	$ (114)	$ 20,305

FINANCIAL INSTRUMENTS - RISK _8

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of fair value of financial instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Warrants Liabilities
Fair value of financial liabilities
Financial liabilities	$ 0	$ 0	$ 1,392
Price adjustment shares
Fair value of financial liabilities
Financial liabilities	114	19,898
Recurring | Level 3
Fair value of financial liabilities
Financial liabilities	28,252	20,305
Recurring | Warrants Liabilities | Level 3
Fair value of financial liabilities
Financial liabilities	0	0
Recurring | SPAC public warrant | Level 3
Fair value of financial liabilities
Financial liabilities	0	286
Recurring | SPAC private warrant | Level 3
Fair value of financial liabilities
Financial liabilities	0	121
Recurring | Advanced payments from MDA against future orders | Level 3
Fair value of financial liabilities
Financial liabilities	28,138	0
Recurring | Price adjustment shares | Level 3
Fair value of financial liabilities
Financial liabilities	$ 114	$ 19,898

FINANCIAL INSTRUMENTS - RISK _9

FINANCIAL INSTRUMENTS - RISK MANAGEMENT - Schedule of warrant liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivatives Liabilities
Change in fair value of liabilities
Balance at beginning	$ 0	$ 1,392
Exercise of warrants to shares	0	(397)
Changes in fair value recognized in finance expenses	0	(195)
Exercise of warrants to cash (adjustment to other accounts payables)	0	(800)
Balance at ending	0	0
SPAC Warrant
Change in fair value of liabilities
Balance at beginning	407
Issuance of warrants	0
Exercise of warrants to shares	0
Changes in fair value recognized in finance expenses	407
Balance at ending	0	407
Price adjustment shares
Change in fair value of liabilities
Balance at beginning	19,898
Changes in fair value recognized in finance expenses	(19,784)
Balance at ending	$ 114	$ 19,898

OTHER LONG-TERM LIABILITIES (Na

OTHER LONG-TERM LIABILITIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2023
Bottom of range [member]
Other Long Term Liabilities [Line Items]
Royalties payable, as a percentage of sales	3%
Top of range [member]
Other Long Term Liabilities [Line Items]
Royalties payable, as a percentage of sales	4%

OTHER LONG-TERM LIABILITIES - S

OTHER LONG-TERM LIABILITIES - Schedule of other long term liabiluties (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Other Long Term Liabilities [Abstract]
Liability for IIA Royalties	$ 1,196	$ 1,107	$ 1,368
Alta settlement	300	0
OTHER LONG TERM LIABILITIES	$ 1,496	$ 1,107

OTHER LONG-TERM LIABILITIES -_2

OTHER LONG-TERM LIABILITIES - Schedule of reconciliation of changes in liability for royalties payable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Other Long Term Liabilities [Abstract]
At January 1	$ 1,107	$ 1,368
Principal Payments	(11)	(429)
Amounts recognized as an offset from research and development expenses	(113)	(210)
Revaluation of the liability	213	378
As of December 31	$ 1,196	$ 1,107

FORWARD PURCHASE AGREEMENT - (N

FORWARD PURCHASE AGREEMENT - (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2023 USD ($) shares	Oct. 27, 2022 USD ($) Year $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 23, 2023 USD ($)
Disclosure of detailed information about business combination [line items]
Funds paid for the shares		$ 86,500	$ 0	$ 1,362	$ 0
Cash transferred						$ 10,000
Equity interests of acquirer						8,400
Vellar Opportunity Fund Spv Llc [Member]
Disclosure of detailed information about business combination [line items]
Equity interests of acquirer						$ 1,600
Vellar Opportunity Fund Spv Llc [Member] | Forward Purchase Agreement [Member] | Business combinations [member]
Disclosure of detailed information about business combination [line items]
Risk-free rate		4.30%
Volatility		50%
Contractual time | Year		3
Share price | $ / shares		$ 8.29
Vellar and ACM [Member] | Termination Agreement [Member]
Disclosure of detailed information about business combination [line items]
Ordinary shares rights termination | shares	3,599,444
Aggregate amount in installments	$ 6,500
Total amount payable	$ 3,700

FORWARD PURCHASE AGREEMENT (Det

FORWARD PURCHASE AGREEMENT (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure Of Forwared Purchase Agreement [Abstract]
At January 1	$ 0
FPA (SPAC transactions)- Assets	42,502
FPA (SPAC transactions)- Liability	(13,306)
FPA (SPAC transactions) net	29,196
Revaluation as of 21.11.2022	(36,692)
Issuance of shares in 21.11.2022	49,998
Revaluation as of 31.12.2022	(1,650)
As of December 31, 2023	40,852
Cash received	(10,026)
Revaluation as of October 2023	(37,408)
Termination	(6,582)
As of December 31	$ 0

EQUITY - Schedule of share opti

EQUITY - Schedule of share option plan Narrative (Details)			12 Months Ended
	May 04, 2017 $ / shares shares	Sep. 04, 2013 $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Share Option Plan
Number of options granted			0	1,405
Number of options exercised by employees			38	226
Number of options outstanding			6,215	7,297	7,710
Number of options exercisable			3,171	3,169
Share split exchange ratio			1.046
Restricted share units [member]
Share Option Plan
Number of options granted			7,808,280
Number of options outstanding			5,219,101
Vesting period of options			3 years
2013 Share Incentive Plan
Share Option Plan
Number of ordinary stock that each option is exercisable into | shares		1
Par value per ordinary share | $ / shares		$ 0.008
Term of the stock options		10 years
Number of options granted			1,405,568
Number of options exercised by employees			229,760	225,964
Number of options outstanding			6,214,912	7,297,303
Number of options exercisable			2,669,614
EMI Share Option Plan
Share Option Plan
Number of ordinary stock that each option is exercisable into | shares	1
Par value per ordinary share | $ / shares	$ 0.008
Term of the stock options	10 years
Vesting period of options	3 years

EQUITY - Schedule of fair value

EQUITY - Schedule of fair value assumptions of share options Narrative (Details) - Year	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Option Plan
Dividend yield (as a percent)	0%	0%
Minimum
Share Option Plan
Expected volatility (as a percent)	40%	40%
Risk-free interest rate (as a percent)	0.10%	0.10%
Term of the stock options	2	2
Maximum
Share Option Plan
Expected volatility (as a percent)	60%	60%
Risk-free interest rate (as a percent)	2.50%	2.50%
Term of the stock options	4	4

EQUITY - Share options outstand

EQUITY - Share options outstanding and exercisable (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)
Share options outstanding and exercisable
Number of options outstanding	6,215	7,297	7,710
Number of options exercisable	3,171	3,169
Options Exercisable, Exercise Price | $ / shares	$ 0.9	$ 0.87
Stock options outstanding, one
Share options outstanding and exercisable
Number of options outstanding	768
Options Outstanding, Weighted Average Remaining Contractual Life	1 year 21 days
Number of options exercisable	768
Options Exercisable, Exercise Price | $ / shares	$ 0.0001
Stock options outstanding, two
Share options outstanding and exercisable
Number of options outstanding	563
Options Outstanding, Weighted Average Remaining Contractual Life	2 months 1 day
Number of options exercisable	563
Options Exercisable, Exercise Price | $ / shares	$ 0.536
Stock options outstanding, three
Share options outstanding and exercisable
Number of options outstanding	260
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 5 months 15 days
Number of options exercisable	260
Options Exercisable, Exercise Price | $ / shares	$ 0.55
Stock options outstanding, four
Share options outstanding and exercisable
Number of options outstanding	1,162
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 3 months 3 days
Number of options exercisable	1,095
Options Exercisable, Exercise Price | $ / shares	$ 1.102
Stock options outstanding, five
Share options outstanding and exercisable
Number of options outstanding	3,462
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 1 month 6 days
Number of options exercisable	485
Options Exercisable, Exercise Price | $ / shares	$ 2.5

EQUITY - Schedule of number of

EQUITY - Schedule of number of share options and weighted average exercise price (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Disclosure of classes of share capital [abstract]
Number of Options, Outstanding at the beginning of year | $	7,297	7,710
Number of Options, Changes during the year:
Number of options granted | $	0	1,405
Number of options exercised | $	38	226
Number of Options, Forfeited | $	1,044	1,592
Number of Options, Outstanding at end of year | $	6,215	7,297
Number of options exercisable | $	3,171	3,169
Weighted Average Exercise Price, Options outstanding at the beginning of year | $ / shares	$ 1.76	$ 1.72
Weighted Average Exercise Price, Changes during the year:
Weighted Average Exercise Price, Granted | $ / shares	0	2.5
Weighted Average Exercise Price, Exercised | $ / shares	0.68	0.42
Weighted Average Exercise Price, Forfeited | $ / shares	2.38	0.22
Weighted Average Exercise Price, Options outstanding at end of year | $ / shares	1.67	1.76
Options Exercisable, Exercise Price | $ / shares	$ 0.9	$ 0.87

EQUITY - Schedule of RSUs to em

EQUITY - Schedule of RSUs to employees and services providers outstanding (Details) - Restricted share units [member]	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [line items]
Outstanding at beginning of year	0
Granted	7,808,280
Vested	(902,753)
Forfeited	(1,686,426)
Unvested as of December 31, 2023	5,219,101

MATERIAL COMMITMENTS - Narrativ

MATERIAL COMMITMENTS - Narrative (Details) - USD ($) shares in Thousands	1 Months Ended	12 Months Ended
	Oct. 27, 2022	Dec. 31, 2023	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2020
MATERIAL COMMITMENTS
Government grants to finance it's research and development programs		$ 6,334,000
Royalty amount included in government grants		$ 3,289,000
Secured overnight financing rate description		Secured Overnight Financing Rate, the SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest will be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.
Maximum royalty to government grants (in percent)		100%
Accrued royalty expense				$ 314,000	$ 916,000
Contingent liability		$ 1,107,000		$ 1,368,000
Discounting interest rate on royalty		20%	20%
Royalty commitments descriptions		Royalties are payable at the rate of 3%-4% from the time of commencement of sales of all of the Company’s products until the cumulative amount of the royalties paid equals 100% of the dollar-linked amounts of the grants received, plus interest at LIBOR.
Proceeds from private investment in public equity		$ 20,000,000
Subscription Agreement With Sensegain Prodigy Cayman Fund [Member]
MATERIAL COMMITMENTS
Number of plaintiffs claim provided to certain service providers		2,000,000
Agreement amount	$ 29,100,000
Proceeds from private investment in public equity	$ 20,000,000	$ 2,300,000
Settlement Agreement With Alta Partners [Member]
MATERIAL COMMITMENTS
Proceeds from private investment in public equity		$ 2,300,000
Minimum
MATERIAL COMMITMENTS
Agency participation in cost (in percent)		50%
Royalty to be paid on total sales of these programs (in percent)		3%
Accrued royalty expense to revenue (in percent)		3%
Maximum
MATERIAL COMMITMENTS
Agency participation in cost (in percent)		75%
Royalty to be paid on total sales of these programs (in percent)		4%
Accrued royalty expense to revenue (in percent)		4%

REVENUES - Schedule of revenues

REVENUES - Schedule of revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUES
Revenues	$ 10,730	$ 10,626	$ 21,720
US
REVENUES
Revenues	8,446	9,310	13,196
Canada
REVENUES
Revenues	8,446	9,310	13,196
UK
REVENUES
Revenues	732	1,070	7,325
Other
REVENUES
Revenues	1,552	246	1,199
Jet talk Limited (“Jet-Talk”)
REVENUES
Revenues	$ 0	$ 0	$ 3,116
Percentage of revenues	0%	0%	14%
Airbus
REVENUES
Revenues	$ 188	$ 318	$ 3,256
Percentage of revenues	2%	3%	15%
Telest
REVENUES
Revenues	$ 4,250	$ 5,326	$ 8,400
Percentage of revenues	40%	50%	39%
Revenues from ST Engineering iDirect ("iDirect")
REVENUES
Revenues	$ 2,605	$ 489	$ 2,074
Percentage of revenues	24%	5%	10%
Trustcom
REVENUES
Revenues	$ 0	$ 1,108	$ 0
Percentage of revenues	0%	10%	0%
MDA
REVENUES
Revenues	$ 1,497	$ 1,907	$ 0
Percentage of revenues	14%	18%	0%
Confidential Customer
REVENUES
Revenues	$ 1,309	$ 1,162	$ 0
Percentage of revenues	12%	11%	0%

COST OF SALES AND SERVICES - Sc

COST OF SALES AND SERVICES - Schedule of cost of sales and service (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cost Of Revenue And Service Abstract
Salaries and related expenses	$ 2,861	$ 3,556	$ 6,764
Materials and models	2,276	707	1,516
Depriciation	34	21	56
Chip Development tools and Subcontractors	767	214	507
Total cost of sales and services	$ 5,938	$ 4,498	$ 8,843

RESEARCH AND DEVELOPMENT EXPE_3

RESEARCH AND DEVELOPMENT EXPENSES, NET - Schedule of research and development expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Research And Development Expenses [Abstract]
Salaries and related expenses, including Stock Based Compensation	$ 23,450	$ 21,923	$ 18,810
Chip pre-production and Development tools	9,917	7,214	12,936
Government support and grants	(4,241)	(12,295)	(13,802)
Total	$ 29,126	$ 16,842	$ 17,944

SELLING AND MARKETING EXPENSES_

SELLING AND MARKETING EXPENSES: - Schedule of selling and marketing expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
SELLING AND MARKETING EXPENSES
Sales and marketing expense	$ 2,866	$ 2,335	$ 1,752
Salaries and related expenses
SELLING AND MARKETING EXPENSES
Sales and marketing expense	$ 2,866	$ 2,335	$ 1,752

ADMINISTRATIVE AND GENERAL EX_3

ADMINISTRATIVE AND GENERAL EXPENSES (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 27, 2022	Dec. 31, 2023
Administrative And General Expenses [Line Items]
Proceeds From Private Investment In Public Equity		$ 20
Subscription Agreement With Sensegain Prodigy Cayman Fund [Member]
Administrative And General Expenses [Line Items]
Proceeds From Private Investment In Public Equity	$ 20	$ 2.3

ADMINISTRATIVE AND GENERAL EX_4

ADMINISTRATIVE AND GENERAL EXPENSES - Schedule of administrative and general expenses (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
ADMINISTRATIVE AND GENERAL EXPENSES
General and administrative expenses		$ 14,561	$ 9,249	$ 3,735
Salaries and related expenses
ADMINISTRATIVE AND GENERAL EXPENSES
General and administrative expenses		5,925	8,175	3,233
Depreciation and overheads
ADMINISTRATIVE AND GENERAL EXPENSES
General and administrative expenses		93	132	240
Expected Credit Loss
ADMINISTRATIVE AND GENERAL EXPENSES
General and administrative expenses	[1]	1,876	0	0
Other expenses
ADMINISTRATIVE AND GENERAL EXPENSES
General and administrative expenses	[2]	$ 6,667	$ 942	$ 262
[1]Write off of a contract asset relating to Jet-Talk contract asset balance, as the Company does not believe it can benefit from the remaining asset due to certain disagreement between the parties, which are under discussion and expected to be resolved in the near future.[2]In 2023 expenses occurred following the Alta settlement of $2.3 million (see Note 19) and new D&O Insurance policy expenses.

LISTING EXPENSES - Schedule of

LISTING EXPENSES - Schedule of net assets (Details) - Endurance Acquisition Corp [Member] - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 27, 2022	Dec. 31, 2023
Disclosure of detailed information about business combination [line items]
Price Adjustment Shares	$ 212,675	$ 212,575	[1]
Issuance of shares	149,657	$ 149,628	[2]
Private Warrants	1,681
Public Warrants	2,203
PIPE Warrants	22
Net Liability of Business Combination	687
Forward Purchase Agreement- Liabilities	13,306
Increase (decrease) liabilities	380,231
Total Cash	(7,813)
Forward Purchase Agreement- Assets	(42,502)
Increase (decrease) in asset (liability)	(50,315)
Other Listing Expenses	3,410
Total	$ 333,326
[1]See note 15.[2]Price based on the market price prior to the SPAC transaction.

LISTING EXPENSES - Schedule o_2

LISTING EXPENSES - Schedule of listing expenses of one-time non-recurring nature (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
		Oct. 27, 2022	Dec. 31, 2023
Disclosure of detailed information about business combination [line items]
Forward Purchase Agreement- Liabilities , Total Amount			$ (13,306)
Forward Purchase Agreement- Assets , Total Amount			$ 42,502
Endurance Acquisition Corp [Member]
Disclosure of detailed information about business combination [line items]
Price Adjustment Shares, Quantity			27,500
Premium- SPAC shares, Quantity			14,800
Warrants, Quantity			18,630
Forward Purchase Agreement- Liabilities , Quantity			1,605
Price Adjustment Shares,Price			$ 7.73
Premium- SPAC shares, Price			10.11
Warrants, Price			0.22
Forward Purchase Agreement- Liabilities , Price			$ 8.29
Price Adjustment Shares, Total Amount		$ 212,675	$ 212,575	[1]
Premium- SPAC shares, Total Amount		$ 149,657	149,628	[2]
Warrants, Total Amount	[3]		4,099
Forward Purchase Agreement- Liabilities , Total Amount	[3]		13,305
Forward Purchase Agreement- Assets , Total Amount	[4]		$ 42,502
[1]See note 15.[2]Price based on the market price prior to the SPAC transaction.[3]Price based on the public price in the closing date.[4]See note 17.

TAX EXPENSES - Schedule of tax

TAX EXPENSES - Schedule of tax expenses Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
TAXES ON INCOME
Loss carryforward	$ 86
UK
TAXES ON INCOME
Corporate tax rate	19%	19%
Israel
TAXES ON INCOME
Corporate tax rate	23%	23%
Developed areas in Israel
TAXES ON INCOME
Corporate tax rate	6%	6%

LOSS PER SHARE - Schedule of lo

LOSS PER SHARE - Schedule of loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Calculation of basic earnings per share:
Net loss	$ (29,715)	$ (397,789)	$ (17,050)
Loss attributed to ordinary shareholders in USD	$ (29,715)	$ (397,789)	$ (17,050)
Weighted average number of ordinary shares, Basic	80,974,653	30,030,805	18,732,473
Weighted average number of ordinary shares, Diluted	80,974,653	30,030,805	18,732,473
Basic loss per share attributed in USD	$ (0.37)	$ (13.25)	$ (0.91)
Diluted loss per share attributed in USD	$ (0.37)	$ (13.25)	$ (0.91)